Document:

Exhibit 10.2

 

Final Version

PATENT TRANSFER AGREEMENT

 

THIS AGREEMENT is made as of May 11,
2005 by and between Schering Aktiengesellschaft, a German corporation having
its principal place of business at Müllerstraße 178, 13353 Berlin, Germany
(hereinafter referred to as “Schering”) and Acusphere, Inc., a Delaware
corporation having its place of business at 500 Arsenal Street, Watertown, MA
02472, USA (hereinafter referred to as “Acusphere”). Schering and Acusphere are
sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

WITNESSETH:

 

WHEREAS, on December 16,
2004 Schering and Acusphere have entered into a Confidentiality Agreement with
respect to information regarding ultrasound contrast agents and related patents
and patent applications;

 

WHEREAS, Acusphere
indicated its interest in acquiring the Ultrasound Patents (hereinafter
defined);

 

WHEREAS, Schering and
Acusphere have previously entered into a non-binding term sheet (the “Term
Sheet”) regarding the acquisition of the Ultrasound Patents by Acusphere and
wish to incorporate the terms and conditions of such Term Sheet in more detail
in a binding agreement.

 

NOW, THEREFORE, the
Parties hereby agree as follows:

 

Article I - Definitions

 

“Affiliate”
shall mean, with respect to a Party, any person, corporation, firm, joint
venture, or other entity which, directly or indirectly, by itself or through
one or more intermediaries, controls, is controlled by, or is under common
control with such Party.  As used in this
definition, the term “control” shall mean the possession of the power to direct
or cause the direction of the management and policies of an entity, whether
through the ownership of at least 50 % of the outstanding voting securities or
by contract or otherwise.

 

“Business Day”
shall mean a day which is not a Saturday, a Sunday or other day on which banks
are required or authorized by law to be closed in the United States, or in
Berlin, Germany.

 

 

“Confidential
Information” shall have the meaning set forth in Section 4.1.

 

“Effective Date”
shall mean the date first written above.

 

“Harmonic Imaging Patents” shall mean all
world-wide pending patent applications and all patents in the field of harmonic
imaging as listed in Appendix C,
including any continuation, continuation-in-part, divisional, provisional or
any substitute application, any patent issued with respect to any such patent
applications, any reissue, reexamination, renewal or extension (including any
supplemental patent certificate or certificate of protection) of any such
patent, and all foreign counterparts existing at the Effective Date which are
the subject matter of the claims of any of the foregoing.

 

“Losses” shall
have the meaning set forth in Section 6.1.

 

“Third Party”
shall mean any entity other than Acusphere or Schering or their respective
Affiliates.

 

“Third Party Rights” shall mean the contracts and agreements relating to the Ultrasound
Patents or Ultrasound Trademarks as listed in Appendix B.

 

“Ultrasound Patents”
shall mean all world-wide pending patent applications and all patents in the
ultrasound field, but not including the Harmonic Imaging Patents, as listed in Appendix A, including any continuation,
continuation-in-part, divisional, provisional or any substitute application,
any patent issued with respect to any such patent applications, any reissue,
reexamination, renewal or extension (including any supplemental patent
certificate or certificate of protection) of any such patent, and all foreign
counterparts, and all inventions existing at the Effective Date which are the
subject matter of the claims of any of the foregoing.

 

“Ultrasound Trademarks” shall mean the trademarks EchovistÒ and LevovistÒ.

 

Article II - Transfer of
Ultrasound Patents; License Grant

 

2.1                                 As
of the Effective Date, Schering hereby sells, assigns and transfers to
Acusphere all right, title and interest in and to the Ultrasound Patents,
including, but not limited to, all claims for damages already incurred, and the
right to sue for past infringement. Acusphere accepts such transfer and
assignment. The Ultrasound Trademarks are not part of the transfer. Neither
Schering nor any of its Affiliates owns any trademarks 

 

2

 

relating to ultrasound
contrast agents other than the Ultrasound Trademarks.   For the avoidance of doubt, Schering makes
no sale, assignment and/or transfer of any right, title and interest in or to
the Third Party Rights.  Acusphere
accepts no responsibility or liability under or arising out of any Third Party
Rights; provided that, Acusphere acknowledges and agrees that the non-exclusive
licenses previously granted by Schering in the Third Party Rights to certain of
the Ultrasound Patents shall hereafter continue in effect in accordance with
the terms and conditions of such Third Party Rights.

 

2.2                                 As
of the Effective Date and subject to the terms and conditions contained herein,
Acusphere hereby grants to Schering and its Affiliates a non-exclusive,
royalty-free, worldwide license under the Ultrasound Patent family
corresponding to EP 0 365 467 B1 (Schering No. 50111)  (the “Licensed Patents”) with the right to
sublicense, to use, make or have made, promote, sell and have sold its
ultrasound product LevovistÒ;
provided that each sublicensee is bound by a written agreement which contains
terms and conditions at least as protective of the Licensed Patents as those
contained herein.  Except for the limited
licenses expressly granted in this Section 2.2, Acusphere retains all
right, title and interest in and to the Licensed Patents.

 

2.2.1    Schering
agrees to promptly notify Acusphere in writing of any actual or threatened
infringement by a third party of any Licensed Patents or of any claim of
invalidity or unenforceability of the Licensed Patents.  Acusphere shall have the right, but not the
obligation, to prosecute or defend such claims, as applicable.  Schering shall, if requested by Acusphere,
provide reasonable assistance to Acusphere, at Acusphere’s expense, in
connection with the prosecution or defense of such claims.

 

2.3                                 Schering
shall be responsible for the execution, delivery and filing of  any and all documents or instruments
necessary to vest full title to the Ultrasound Patents in Acusphere.
Accordingly, Schering shall, on the Effective Date (or as promptly thereafter
as is practicable), provide all declarations and sign, deliver and file all
documents (or procure that such documents are signed, delivered and filed) that
are necessary for the assignment and transfer of the Ultrasound Patents and/or their
re-registration in the name of Acusphere or an Acusphere Affiliate. Acusphere
acknowledges that in order to fulfill its obligations hereunder Schering needs
prompt information from Acusphere on the name of the Acusphere Affiliate, in
which the full title to the Ultrasound Patents shall be vested, if not directly
in Acusphere. In addition, Schering needs to promptly know  the patent counsel of Acusphere who shall be
responsible for the Ultrasound Patents thereafter in the respective countries.
Any 

 

3

 

costs associated with
the assignment and transfer of the Ultrasound Patents shall be borne by
Schering.

 

2.4                                 Schering
irrevocably covenants to Acusphere that it will not and will ensure that none
of the Schering Affiliates initiate, assist any third party, or otherwise
participate in, except where such participation is required pursuant to a
judicial or regulatory order or subpeona, in any claim, proceeding, suit or
other similar action to invalidate or otherwise challenge the validity or
enforceability of any of the Ultrasound Patents.

 

2.5                                 Schering
shall have paid any annuity, renewal, or administrative fee related to the
Ultrasound Patents that are due on or before the Effective Date.  As of the Effective Date, Acusphere shall be
responsible for any annuity, renewal or administration fee related to each of
the Ultrasound Patents; provided, however, (a) in order to permit
Acusphere or an Acusphere Affiliate adequate time to assume full administrative
responsibility for the payment of any annuity, renewal or administrative fees
due for the Ultrasound Patents after the Effective Date, Schering agrees to
arrange to pay any such annuity, renewal or administration fee due on the
Ultrasound Patents within ninety (90) days of the Effective Date (or until such
time as Acusphere or an Acusphere Affiliate advises Schering, in writing, that
it no longer requires the annuity, renewal or administration fees so due),
Acusphere or an Acusphere Affiliate to reimburse Schering for any such fees,
and (b) Acusphere shall have no obligation to prosecute or maintain any
Ultrasound Patent that it determines, in its sole discretion, to abandon or
lapse; provided that Acusphere shall give Schering notice of its intention to
abandon any of the Licensed Patents and Schering shall have the right, but not
the obligation, to assume responsibility for the payment of maintenance
fees.  Fees already paid by Schering
prior to the Effective Date shall neither totally nor partially be charged back
to Acusphere in any way.

 

2.6                                 Schering
shall, on the Effective Date, deliver to Acusphere all copies in its or its
counsel’s possession of files relating to the prosecution and defense of all of
the Ultrasound Patents, including, without limitation, the entire “file wrapper”
(prosecution history) of all issued and pending Ultrasound Patents, including
official correspondence (office actions, amendments, etc.) to and from, and
notes of telephone conversations with, any U.S. and foreign governmental or
regulatory authority regarding all of the Ultrasound Patents.  After the Effective Date, Schering is willing
to assist Acusphere, to the extent that Schering’s internal resources and
capabilities allow, in the filing and prosecution of any patent applications included
in the Ultrasound Patents and in the defense of any of the Ultrasound Patents
before the U.S. Patent and Trademark Office and equivalent foreign governmental

 

4

 

authorities.  Acusphere shall reimburse Schering for the
reasonable cost of any such cooperation.

 

2.7                                 Schering hereby grants Acusphere and each
Acusphere Affiliate an irrevocable (except as otherwise set forth in Section 7.3),
non-exclusive, royalty-free, fully paid up, non-sublicenseable, worldwide,
perpetual  right and license to use the
Harmonic Imaging Patents solely in connection with exercising its rights in and
to any and all of the Ultrasound Patents or in connection with the manufacture, use,
importation, or sale of ultrasound
contrast agents owned or controlled by Acusphere, including without limitation, the right and
license to develop, have developed, manufacture, have manufactured, market,
promote, sell, have sold, offer for sale, have offered for sale, import, have
imported, rent, provide and/or lease products or services which practice or
embody, or are configured for use in practicing, the Harmonic Imaging Patents
and the right to practice any method covered by the Harmonic Imaging Patents.

 

Article III - Payments;
Payment Terms

 

3.1                                In
consideration of the assignment and transfer of the Ultrasound Patents,
Acusphere shall pay to Schering an overall amount of $7,000,000 (seven million
USD) to be paid in the following installments:

 

•                  $ 1,000,000.00 (one million USD) within 15 Business
Days of the Effective Date of this Agreement;

•                  $ 3,000,000.00 (three million USD) within 15
Business Days of the first anniversary of the Effective Date of this Agreement;

•                  $ 3,000,000.00 (three million USD) within 15
Business Days of the second anniversary of the Effective Date of this
Agreement.

 

All
payments are due as listed above without invoice and shall be made to a bank
account to be notified by Schering in due time. For any delayed payment
Schering has the right to charge computed interest to Acusphere at Prime
Rate as quoted on internet page ‘http://www.bankofamerica.com/facts/index.cfm?Menu_Sel=primerate’”plus
a premium of 3% p.a. computed on
the basis of act/360 year, such interest to be due and payable upon tender of
the payment.

 

5

 

Article IV –
Confidentiality; Public Announcements

 

4.1                                 Except to the extent expressly authorized by
this Agreement or otherwise agreed in writing, the Parties agree that the
receiving Party shall keep confidential and shall not publish or otherwise
disclose or use for any purpose other than as provided for in this Agreement
any Confidential Information of the other Party.  As used herein, “Confidential Information”
means any information and materials other than the Ultrasound Patents or
Harmonic Imaging Patents furnished to a Party by the other Party pursuant to
this Agreement that (a) the disclosing Party has marked as confidential or
proprietary, or (b) the disclosing Party identifies as confidential at the
time of oral disclosure with written confirmation within 15 days of disclosure
to the receiving Party; provided, that the provisions of this Agreement
will be deemed Confidential Information of both Parties; provided, further
however, that reports and/or information related to or regarding the
disclosing Party’s business plans, business methodologies, strategies,
technology, specifications, development plans, customers, prospective
customers, billing records, and products or services will
be deemed Confidential Information of the disclosing Party even if not so
marked or identified, except to the extent that it can be established by the
receiving Party that such Confidential Information:

 

(a)                                  was already known to the receiving Party, other
than under an obligation of confidentiality, at the time of disclosure by the
other Party, as evidenced by written records maintained by the receiving Party
in the ordinary course of business; or

 

(b)                                 was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the
receiving Party; or

 

(c)                                  became generally available to the public or
otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving Party in breach of this Agreement; or

 

(d)                                 was disclosed to the receiving Party, other
than under an obligation of confidentiality, by a Third Party who had no
obligation to the disclosing Party not to disclose such information to others.

 

4.2                                 Each Party may disclose Confidential Information
hereunder to the extent such disclosure is reasonably necessary to comply with
applicable governmental laws, rules and regulations, including, without
limitation, those of the U.S. Food and Drug Administration (“FDA”) and
Securities and Exchange Commission.  If a
Party is required by law or regulation to make any such disclosure of the other
Party’s Confidential Information it will give reasonable advance notice to the
other Party of 

 

6

 

such disclosure requirement and shall permit the other
Party to intervene therein to protect its interests in its Confidential
Information, and provide full cooperation and assistance to other Party in
seeking to obtain such protection; provided, however, that none of the rights
and obligations set forth in this sentence shall apply to any such disclosure
by Acusphere in a Form 8-K or Form 10-Q which is filed with the
Securities and Exchange Commission within 45 days of the Effective Date.

 

4.3                                 Notwithstanding any of the foregoing to the
contrary, Acusphere may prepare and issue a press release announcing and
describing this Agreement and the transaction contemplated hereby.  At least 5 (five) Business Days prior to
releasing such press release, Acusphere shall give Schering the opportunity to
review and comment thereon. Acusphere shall refer to Schering in such release
as “Schering AG, Germany”.

 

4.4                                 Except as set forth in Section 4.3,
neither Party shall use the name of the other Party or any Affiliate of the
other Party in relation to this Agreement or the transactions described herein
in any public announcement, press release or other public document without the
written consent of such other Party, which consent shall not be unreasonably
withheld, conditioned or delayed; provided, however, that either Party may use
the name of the other Party in any document filed with any regulatory agency or
authority to comply with legal or regulatory requirements, including the FDA
and the Securities and Exchange Commission, in which cases Acusphere shall
refer to Schering as “Schering AG, Germany”. 
Notwithstanding the foregoing, Schering agrees not to disclose the terms
of this Agreement to its sublicensees within 90 days after the Effective Date.

 

4.5                                This Article IV shall survive termination
or expiration of this Agreement.

 

Article V - Representations and Warranties;
Limitation

 

5.1                                Each of the Parties represents and warrants to
the other Party that (a) it has full right, power and authority to execute
and deliver this Agreement and to consummate the transactions contemplated
hereby, (b) this Agreement is a legal and valid obligation binding upon
such Party and enforceable in accordance with its terms, and (c) the
execution, delivery and performance of the Agreement by such Party does not
conflict with any agreement, instrument or understanding, oral or written, to
which it is a Party or by which it is bound, nor to such Party’s knowledge,
violate any law or regulation of any court, governmental body or administrative
or other agency having jurisdiction over it.

 

7

 

5.2                                Schering hereby represents and warrants to
Acusphere that

 

(a)                        Schering is the rightful and exclusive owner of
all right, title and interest in and to the Ultrasound Patents;

 

(b)                       the Ultrasound Patents are free and clear of
any liens, license rights, security interests, encumbrances or rights to
repurchase, other than those listed in Appendix B;

 

(c)                        each of the Ultrasound Patents is properly
filed or issued, as applicable, currently in compliance with formal legal
requirements (including, without limitation, payment of filing, examination and
governmental taxes and maintenance fees) and enforceable and, to the knowledge
of Schering or any of its Affiliates, valid.

 

(d)                       there are no pending, or, to the knowledge of
Schering or any of its Affiliates, threatened claims against Schering or any of
its Affiliates claiming that the making, using, selling, offering for sale or
importing of products or services which are covered by the subject matter of
the claims of the Ultrasound Patents infringe on or violate any patent or other
intellectual property right of a person or entity or that any of the Ultrasound
Patents is invalid or unenforceable and Schering is not aware of any facts or
circumstances that would form the basis for a determination that any of such
Ultrasound Patents are invalid or unenforceable.

 

(e)                        to the knowledge of Schering or any of its
Affiliates, the making, using, selling, offering for sale or importing of products
or services which are covered by the subject matter of the claims of the
Ultrasound Patents does not infringe on or violate (or in the past did not
infringe on or violate) any patent or other intellectual property right of a
person or entity.

 

(f)                          to the knowledge of Schering or any of its
Affiliates, there is no, nor has there been any, infringement or violation or
alleged infringement or violation by any person or entity of any of Schering’s
rights in or to the Ultrasound Patents.

 

(g)                       All licenses or other agreements under which
Schering has granted rights to others in the Ultrasound Patents are listed in Appendix B attached hereto. 
All such licenses or other agreements are in full force and effect, and,
to the 

 

8

 

knowledge of Schering there is no material default by
any Party thereto.  True and complete
copies of all such licenses or other agreements, and any amendments thereto,
have been provided to Acusphere with certain limited redactions thereto, and
Schering has all requisite power and authority to grant the rights purported to
be conferred thereby.

 

(h)                       Appendix
A
comprises a complete and accurate listing of all patents and patent
applications owned or controlled by Schering or any Affiliate of Schering in
the ultrasound field; and  Appendix C comprises a complete and accurate listing of all
Harmonic Imaging Patents owned or controlled by Schering or any Affiliate of
Schering.

 

5.3                                EXCEPT AS SET FORTH ABOVE IN SECTION 5.2,
EACH PARTY MAKES NO AND DISCLAIMS ANY OTHER WARRANTY OR REPRESENTATION, EXPRESS
OR IMPLIED, CONCERNING THE ULTRASOUND PATENTS, INCLUDING ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,

 

Article VI - Indemnification

 

6.1                                Without prejudice to any other right or remedy
available to either Party arising out of the breach by the other of any of the
representations and warranties set out in Sections 5.1 and 5.2 above, each
Party hereby agrees to indemnify, defend and hold the other Party and its
Affiliates, directors, officers, and employees harmless from and against any
and all suits, claims, actions, demands, liabilities, expenses and/or losses,
including reasonable legal expenses and attorneys’ fees (collectively, “Losses”
and each a “Loss”), resulting directly or indirectly from (i) the material
breach of any obligation under this Agreement, or (ii) the material breach
of any representation or warranty made by such Party hereunder; provided
however that neither party shall indemnify the other party for loss of profit.

 

6.2                                Each indemnified Party agrees to give the
indemnifying Party prompt written notice of any Loss or discovery of fact upon
which such indemnified Party intends to base a request for indemnification
under Section 6.1.  Each Party shall
furnish promptly to the other copies of all papers and official documents
received in respect of any Loss. The indemnifying Party shall have the sole
right to defend, settle or otherwise dispose of such Loss, on such terms as the
indemnifying Party, in its sole discretion, shall deem appropriate. The
indemnifying Party shall obtain the written consent of the indemnified Party,
which shall not be unreasonably withheld or delayed, prior to 

 

9

 

ceasing to defend, settling or otherwise disposing of
any Loss if as a result thereof the indemnified Party would become subject to
injunctive or other equitable relief or any remedy other than the payment of
money, which payment would be the responsibility of the indemnifying Party. The
indemnifying Party shall not be liable for any settlement or other disposition
of a Loss by the indemnified Party which is reached without the written consent
of the indemnifying Party. The reasonable costs and expenses, including
reasonable fees and disbursements of counsel incurred by any indemnified Party
in connection with any Loss, shall be reimbursed on a quarterly basis by the
indemnifying Party, without prejudice to the indemnifying Party’s right to
contest the indemnified Party’s right to indemnification and subject to refund
in the event the indemnifying Party is ultimately held not to be obligated to
indemnify the indemnified Party.

 

6.3                                This Article VI shall survive the
termination or expiration of this Agreement.

 

 Article VII - Term and Termination

 

7.1                                This Agreement shall come into force on the
Effective Date and shall continue in effect until the last Ultrasound Patent
licensed back to Schering under Section 2.2 has expired.

 

7.2                                In case that Schering or any of its Affiliates
or sublicensees of Schering or any of Schering’s Affiliates attempts to
challenge the validity or enforceability of the Licensed Patents, Acusphere has
the right to immediately terminate the license granted in Section 2.2
above upon written notice.

 

7.3                                In the event that
Acusphere acquires (whether through a purchase of assets or stock, merger or
otherwise) a Third Party  which,
immediately prior to the closing of such acquisition, is a party to an
effective agreement under which Schering has granted such Third Party a royalty
bearing license under any of the Harmonic Imaging Patents (any such agreement,
a “Harmonic Imaging Patent License”), Acusphere shall promptly notify Schering
of such acquisition.  Thereafter, upon
Schering’s written request, the parties shall amend this Agreement to clarify
that the Harmonic Imaging Patent License royalty obligations with respect to
the Harmonic Imaging Patents covered therein supercede the royalty free license
granted in Section 2.7 above and confirm that Acusphere and/or an Acusphere
Affiliate, as applicable, shall pay all royalties set forth in and subject to
the terms and conditions of the Harmonic Imaging Patent License with respect to
those Harmonic Imaging Patents covered therein.

 

10

 

7.4                                The rights and obligations set forth in this
Agreement shall extend beyond the expiration of this Agreement only to the
extent expressly provided for herein, or to the extent that the survival of
such rights or obligations are necessary to permit their complete fulfillment
or discharge

 

Article VIII - Miscellaneous

 

8.1                                Amendments. No subsequent amendment or addition to this Agreement shall be binding
upon the Parties unless executed in writing and signed by the respective
authorized representatives of the Parties.

 

8.2                                Headings.  The section and paragraph
headings contained herein are for the purposes of convenience only and are not
intended to define or limit the contents of said sections or paragraphs.

 

8.3                                Further Actions.  Each
Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of the Agreement.

 

8.4                                Severability. Each Party hereby agrees that it does not intend, by its execution
hereof, to violate any public policies, statutory or common laws, rules,
regulations, treaties or decisions of any government agency or executive body
thereof of any country or community or association of countries.  Should one or more provisions of this
Agreement be or become invalid, the Parties hereto shall substitute, by mutual
consent, valid provisions for such invalid provisions, which valid provisions
in their economic and other effects are sufficiently similar to the invalid provisions
that it can be reasonably assumed that the Parties would have entered into this
Agreement with such valid provisions.  In
case such valid provisions cannot be agreed upon, the invalidity of one or
several provisions of this Agreement shall not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential
importance to this Agreement that it is to be reasonably assumed that the
Parties would not have entered into this Agreement without the invalid
provision.

 

8.5                                Prior Agreements.  This
Agreement constitutes the full and entire understanding and agreement among the
Parties hereto with respect to the subject matters hereof, and any and all
other written or oral agreements existing prior to or contemporaneously herewith,
including but not limited to, the Term Sheet between the Parties, are hereby
expressly superseded by the provisions of this Agreement. The Confidentiality
Agreement dated December 16, 2004 shall continue to apply.

 

11

 

8.6                                Notices.    All notices, requests, demands and other
communications hereunder shall be in writing and shall be deemed to have been
duly given when delivered personally or when mailed, by certified or registered
mail, prepaid, to the Parties or their assignees at the address set forth above
(or at such other address as shall be given in writing by a Party).

 

8.7                                Governing Law and Dispute Resolution.

 

This
Agreement shall be governed by and construed in accordance with the laws of
Germany. All disputes arising in connection with this Agreement or its validity
which cannot be resolved amicably by the Parties shall be finally settled
according to the rules of the German Institution of Arbitration e.V.
(Deutsches Institut für Schiedsgerichtsbarkeit e.V.) without recourse to the
ordinary courts of law except for interim proceedings (einstweiliger
Rechtschutz). The exclusive place of arbitration shall be Frankfurt
am Main, Germany. The arbitral tribunal shall consist of three arbitrators, one
arbitrator to be appointed by each Party and the third to be appointed by the
Arbitration Institution. The language of the arbitral proceedings shall be
English.

 

IN
WITNESS WHEREOF, Schering and Acusphere have caused this Agreement to be
executed as of the Effective Date by their respective duly authorized
representatives.

 

	
  Acusphere, Inc.

  	
  Schering
  Aktiengesellschaft

  
	
   

  	
   

  
	
  /s/
  Sherri C. Oberg

  	
   

  	
  /s/ H.M.
  Rook

  	
   

  
	
  Name: Sherri C. Oberg

  	
  Name: H.M. Rook

  
	
  Title: President and CEO

  	
  Title: Head of GBU Diagnostic Imaging

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Dr. T.
  Fritzsch

  	
   

  
	
   

  	
  Name: Dr. T.
  Fritzsch

  
	
   

  	
  Title:

  	
  Business
  Development Diagnostic

  
	
   

  	
  Imaging,
  Licensing & Cooperations

  
					

 

12

 

Appendix A - Ultrasound Patents

 

Patent
Family # 03228A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing 

  Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  DE

  	
   

  	
  NP1

  	
   

  	
  05/Feb/1988

  	
   

  	
  P 3803972.9

  	
   

  	
  10/Aug/1989

  	
   

  	
  04/Jul/1989

  	
   

  	
  3803972

  	
   

  	
  GRT

  	
   

  	
  04/Jul/1989

  	
   

  	
  3803972

  	
   

  	
  05/Feb/2008

  	
   

  
	
  DK

  	
   

  	
  PCT1

  	
   

  	
  01/Feb/1989

  	
   

  	
  1864/90

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  03/Aug/1990

  	
   

  	
  1864/90

  	
   

  	
  01/Feb/2009

  	
   

  
	
  US

  	
   

  	
  CNT2

  	
   

  	
  11/Jun/1990

  	
   

  	
  07/536377

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  11/Jun/1990

  	
   

  	
  07/536377

  	
   

  	
   

  	
   

  
	
  US

  	
   

  	
  CNT3

  	
   

  	
  07/Jun/1993

  	
   

  	
  08/072748

  	
   

  	
   

  	
   

  	
  20/Jun/1995

  	
   

  	
  5425366

  	
   

  	
  GRT

  	
   

  	
  20/Jun/1995

  	
   

  	
  5425366

  	
   

  	
  20/Jun/2012

  	
   

  
	
  US

  	
   

  	
  CNT4

  	
   

  	
  13/Feb/1995

  	
   

  	
  08/387612

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  13/Feb/1995

  	
   

  	
  08/387612

  	
   

  	
   

  	
   

  
	
  US

  	
   

  	
  CNT5

  	
   

  	
  07/Jun/1995

  	
   

  	
  08/477642

  	
   

  	
   

  	
   

  	
  06/Jun/2000

  	
   

  	
  6071496

  	
   

  	
  GRT

  	
   

  	
  06/Jun/2000

  	
   

  	
  6071496

  	
   

  	
  06/Jun/2017

  	
   

  
	
  US

  	
   

  	
  CNT6

  	
   

  	
  07/Jun/1995

  	
   

  	
  08/474468

  	
   

  	
   

  	
   

  	
  23/Jan/2001

  	
   

  	
  6177062 B1

  	
   

  	
  GRT

  	
   

  	
  23/Jan/2001

  	
   

  	
  6177062 B1

  	
   

  	
  06/Jun/2017

  	
   

  
	
  US

  	
   

  	
  CNT7

  	
   

  	
  29/Nov/1995

  	
   

  	
  08/563926

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  29/Nov/1995

  	
   

  	
  08/563926

  	
   

  	
  03/Feb/2009

  	
   

  
	
  US

  	
   

  	
  CNT8

  	
   

  	
  24/Feb/2000

  	
   

  	
  09/512473

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  24/Feb/2000

  	
   

  	
  09/512473

  	
   

  	
  03/Feb/2009

  	
   

  

 

A-1

 

Patent
Family # 50111A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  DE

  	
   

  	
  EPA1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
  25/Apr/1990

  	
   

  	
  18/Aug/1993

  	
   

  	
  P 58905318.3-08

  	
   

  	
  GRT

  	
   

  	
  18/Aug/1993

  	
   

  	
  P 58905318.3-08

  	
   

  	
  06/Apr/2009

  	
   

  
	
  DE

  	
   

  	
  SPC1

  	
   

  	
  07/Jun/1996

  	
   

  	
  19675015.6

  	
   

  	
   

  	
   

  	
  13/Dec/1995

  	
   

  	
  32851.00.00

  	
   

  	
  GRT

  	
   

  	
  13/Dec/1995

  	
   

  	
  32851.00.00

  	
   

  	
  21/Jun/2010

  	
   

  
	
  ES

  	
   

  	
  EPA1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
  25/Apr/1990

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  GRT

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  06/Apr/2009

  	
   

  
	
  ES

  	
   

  	
  SPC1

  	
   

  	
  29/Jan/1998

  	
   

  	
  C 9800006

  	
   

  	
   

  	
   

  	
  01/Sep/1999

  	
   

  	
  C 9800006

  	
   

  	
  GRT

  	
   

  	
  01/Sep/1999

  	
   

  	
  C 9800006

  	
   

  	
  21/Jun/2010

  	
   

  
	
  FR

  	
   

  	
  EPA1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
  25/Apr/1990

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  GRT

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  06/Apr/2009

  	
   

  
	
  FR

  	
   

  	
  SPC1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
   

  	
   

  	
  10/Oct/1999

  	
   

  	
  97 C 0008

  	
   

  	
  GRT

  	
   

  	
  10/Oct/1999

  	
   

  	
  97 C 0008

  	
   

  	
  20/Jun/2010

  	
   

  
	
  GB

  	
   

  	
  EPA1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
  25/Apr/1990

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  GRT

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  06/Apr/2009

  	
   

  
	
  GB

  	
   

  	
  SPC1

  	
   

  	
  22/Nov/1996

  	
   

  	
  SPC/GB96/055

  	
   

  	
   

  	
   

  	
  21/Apr/1997

  	
   

  	
  SPC/GB96/055

  	
   

  	
  GRT

  	
   

  	
  21/Apr/1997

  	
   

  	
  SPC/GB96/055

  	
   

  	
  20/Jun/2010

  	
   

  
	
  IT

  	
   

  	
  EPA1

  	
   

  	
  06/Apr/1989

  	
   

  	
  89730095.0

  	
   

  	
  25/Apr/1990

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  GRT

  	
   

  	
  18/Aug/1993

  	
   

  	
  0365467

  	
   

  	
  06/Apr/2009

  	
   

  
	
  IT

  	
   

  	
  SPC1

  	
   

  	
  30/Oct/1996

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  30/Oct/1996

  	
   

  	
   

  	
   

  	
  06/Apr/2014

  	
   

  
	
  JP

  	
   

  	
  NP1

  	
   

  	
  04/Oct/1989

  	
   

  	
  258007/89

  	
   

  	
   

  	
   

  	
  11/Jan/1996

  	
   

  	
  2005630

  	
   

  	
  GRT

  	
   

  	
  11/Jan/1996

  	
   

  	
  2005630

  	
   

  	
  04/Oct/2009

  	
   

  
	
  JP

  	
   

  	
  SPC1

  	
   

  	
  03/Sep/1999

  	
   

  	
  11-700082

  	
   

  	
   

  	
   

  	
  22/Feb/2001

  	
   

  	
  2005630

  	
   

  	
  GRT

  	
   

  	
  22/Feb/2001

  	
   

  	
  2005630

  	
   

  	
  04/Oct/2014

  	
   

  

 

A-2

 

Patent
Family # 50622A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filling

  Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  E 163134

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  E 163134

  	
   

  	
  05/Jun/2013

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  59308146.3-08

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  59308146.3-08

  	
   

  	
  05/Jun/2013

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  EP

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  GR

  	
   

  	
  EPT1

  	
   

  	
  02/Jun/1993

  	
   

  	
  20040400095

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  3026498.B2

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  3026498.B2

  	
   

  	
  02/Jun/2013

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  LU

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  MC

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  19944805

  	
   

  	
   

  	
   

  	
  08/May/2000

  	
   

  	
  307646

  	
   

  	
  GRT

  	
   

  	
  08/May/2000

  	
   

  	
  307646

  	
   

  	
  05/Jun/2013

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777

  	
   

  	
  05/Jun/2013

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  93912897-1

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  93912897-1

  	
   

  	
  05/Jun/2013

  	
   

  
	
  US

  	
   

  	
  PCT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  08/351372

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  13/Dec/1994

  	
   

  	
  08/351372

  	
   

  	
   

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  05/Jun/1993

  	
   

  	
  93912897.1

  	
   

  	
  29/Mar/1995

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777/E78869

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  0644777/E78869

  	
   

  	
  05/Jun/2013

  	
   

  

 

A-3

 

Patent
Family # 50686A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing

  Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  E 173937

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  E 173937

  	
   

  	
  24/Apr/2013

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  CA

  	
   

  	
  PCT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  2137910

  	
   

  	
   

  	
   

  	
  03/Jun/2003

  	
   

  	
  2137910

  	
   

  	
  GRT

  	
   

  	
  03/Jun/2003

  	
   

  	
  2137910

  	
   

  	
  24/Apr/2013

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  59309189.2-08

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  59309189.2-08

  	
   

  	
  24/Apr/2013

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  GR

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  990400590/3029494

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  990400590/3029494

  	
   

  	
  24/Apr/2013

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  LU

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  MC

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  944806

  	
   

  	
   

  	
   

  	
  25/Sep/2000

  	
   

  	
  308510

  	
   

  	
  GRT

  	
   

  	
  25/Sep/2000

  	
   

  	
  308510

  	
   

  	
  24/Apr/2013

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  0644776

  	
   

  	
  24/Apr/2013

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  24/Apr/1993

  	
   

  	
  93911501.0

  	
   

  	
  29/Mar/1995

  	
   

  	
  02/Dec/1998

  	
   

  	
  93911501-0

  	
   

  	
  GRT

  	
   

  	
  02/Dec/1998

  	
   

  	
  93911501-0

  	
   

  	
  24/Apr/2013

  	
   

  

 

A-4

 

Patent
Family #50716A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  E 165517

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  E 165517

  	
   

  	
  08/Sep/2013

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  CA

  	
   

  	
  PCT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  2145505

  	
   

  	
   

  	
   

  	
  17/Feb/2004

  	
   

  	
  CA 2145505

  	
   

  	
  GRT

  	
   

  	
  17/Feb/2004

  	
   

  	
  CA 2145505

  	
   

  	
  08/Sep/2013

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  CN

  	
   

  	
  NP1

  	
   

  	
  25/Sep/1993

  	
   

  	
  93118159.3

  	
   

  	
  20/Jul/1994

  	
   

  	
  06/Feb/2002

  	
   

  	
  80509

  	
   

  	
  GRT

  	
   

  	
  06/Feb/2002

  	
   

  	
  80509

  	
   

  	
  25/Sep/2013

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  59308479.9-08

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  59308479.9-08

  	
   

  	
  08/Sep/2013

  	
   

  
	
  DE

  	
   

  	
  NP1

  	
   

  	
  26/Sep/1992

  	
   

  	
  P 4232755.5

  	
   

  	
  31/Mar/1994

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  31/Mar/1994

  	
   

  	
  DE 4232755 A1

  	
   

  	
  26/Sep/2012

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  FI

  	
   

  	
  PCT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  951379

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  23/Mar/1995

  	
   

  	
   

  	
   

  	
  08/Sep/2013

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  GR

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  980401268/3027050

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  980401268/3027050

  	
   

  	
  08/Sep/2013

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
   

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005/E 80081

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005/E 80081

  	
   

  	
  08/Sep/2013

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  LU

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  MC

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  19951138

  	
   

  	
   

  	
   

  	
  15/May/2000

  	
   

  	
  307692

  	
   

  	
  GRT

  	
   

  	
  15/May/2000

  	
   

  	
  307692

  	
   

  	
  08/Sep/2013

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  0662005

  	
   

  	
  08/Sep/2013

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  93919293.6

  	
   

  	
  12/Jul/1995

  	
   

  	
  29/Apr/1998

  	
   

  	
  93919293.6

  	
   

  	
  GRT

  	
   

  	
  29/Apr/1998

  	
   

  	
  93919293.6

  	
   

  	
  08/Sep/2013

  	
   

  
	
  US

  	
   

  	
  CWO1

  	
   

  	
  21/Jul/1997

  	
   

  	
  08/897319

  	
   

  	
  07/Mar/2002

  	
   

  	
  07/May/2002

  	
   

  	
  6383470 B1

  	
   

  	
  GRT

  	
   

  	
  07/May/2002

  	
   

  	
  6383470 B1

  	
   

  	
  08/Sep/2013

  	
   

  
	
  US

  	
   

  	
  PCT1

  	
   

  	
  08/Sep/1993

  	
   

  	
  08/406882

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  27/Mar/1995

  	
   

  	
  08/406882

  	
   

  	
   

  	
   

  

 

A-5

 

Patent
Family #50902A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing

  Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  CA

  	
   

  	
  PCT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  2171303

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  25/Aug/1994

  	
   

  	
  2171303

  	
   

  	
  25/Aug/2014

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  59409568.9-08

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  59409568.9-08

  	
   

  	
  25/Aug/2014

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  GR

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  20010400035/3035219

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  20010400035/3035219

  	
   

  	
  25/Aug/2014

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  LU

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  MC

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  960973

  	
   

  	
   

  	
   

  	
  04/Mar/2002

  	
   

  	
  312007

  	
   

  	
  GRT

  	
   

  	
  04/Mar/2002

  	
   

  	
  312007

  	
   

  	
  25/Aug/2014

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  0717617

  	
   

  	
  25/Aug/2014

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  94926878.3

  	
   

  	
  26/Jun/1996

  	
   

  	
  25/Oct/2000

  	
   

  	
  94926878.3

  	
   

  	
  GRT

  	
   

  	
  25/Oct/2000

  	
   

  	
  94926878.3

  	
   

  	
  25/Aug/2014

  	
   

  
	
  US

  	
   

  	
  DWO1

  	
   

  	
  13/Dec/1999

  	
   

  	
  09/459578

  	
   

  	
   

  	
   

  	
  04/Sep/2001

  	
   

  	
  6284280 B1

  	
   

  	
  GRT

  	
   

  	
  04/Sep/2001

  	
   

  	
  6284280 B1

  	
   

  	
  25/Aug/2014

  	
   

  
	
  US

  	
   

  	
  PCT1

  	
   

  	
  25/Aug/1994

  	
   

  	
  08/605174

  	
   

  	
   

  	
   

  	
  30/May/2000

  	
   

  	
  6068857

  	
   

  	
  GRT

  	
   

  	
  30/May/2000

  	
   

  	
  6068857

  	
   

  	
  30/May/2017

  	
   

  

 

A-6

 

Patent
family # 51090A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing

  Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  59509618.2-08

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  59509618.2-08

  	
   

  	
  10/Feb/2015

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  JP

  	
   

  	
  PCT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  07-522099

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  10/Feb/1995

  	
   

  	
  07-522099

  	
   

  	
   

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  19963501

  	
   

  	
   

  	
   

  	
  21/May/2002

  	
   

  	
  312497

  	
   

  	
  GRT

  	
   

  	
  21/May/2002

  	
   

  	
  312497

  	
   

  	
  10/Feb/2015

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  0744961

  	
   

  	
  10/Feb/2015

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  95909702.3

  	
   

  	
  04/Dec/1996

  	
   

  	
  19/Sep/2001

  	
   

  	
  95909702.3

  	
   

  	
  GRT

  	
   

  	
  19/Sep/2001

  	
   

  	
  95909702.3

  	
   

  	
  10/Feb/2015

  	
   

  
	
  US

  	
   

  	
  DWO1

  	
   

  	
  06/Aug/1998

  	
   

  	
  09/129953

  	
   

  	
   

  	
   

  	
  23/Oct/2001

  	
   

  	
  6306366 B1

  	
   

  	
  GRT

  	
   

  	
  23/Oct/2001

  	
   

  	
  6306366 B1

  	
   

  	
  10/Feb/2015

  	
   

  
	
  US

  	
   

  	
  PCT1

  	
   

  	
  10/Feb/1995

  	
   

  	
  08/700354

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  21/Oct/1996

  	
   

  	
  08/700354

  	
   

  	
   

  	
   

  

 

A-7

 

Patent
Family #51639A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  AU

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  59627/00

  	
   

  	
  08/Sep/2003

  	
   

  	
  05/Feb/2004

  	
   

  	
  766705

  	
   

  	
  GRT

  	
   

  	
  05/Feb/2004

  	
   

  	
  766705

  	
   

  	
  23/May/2020

  	
   

  
	
  BE

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  CA

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  2373869

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  13/Nov/2001

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  CH

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  CN

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  00811021.2

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  27/Nov/2001

  	
   

  	
  00811021.2

  	
   

  	
  23/May/2020

  	
   

  
	
  CY

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  CZ

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  PV 2001-4235

  	
   

  	
  17/Apr/2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  17/Apr/2002

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  DE

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  50002914.8-08

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  50002914.8-08

  	
   

  	
  23/May/2020

  	
   

  
	
  DE

  	
   

  	
  NP1

  	
   

  	
  27/May/1999

  	
   

  	
  19925311.0

  	
   

  	
  30/Nov/2000

  	
   

  	
  15/Jan/2004

  	
   

  	
  19925311.0-09

  	
   

  	
  GRT

  	
   

  	
  15/Jan/2004

  	
   

  	
  19925311.0-09

  	
   

  	
  27/May/2019

  	
   

  
	
  DK

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  EP

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  ES

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  FI

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  FR

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  GB

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  GR

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  20030404214

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  20030404214

  	
   

  	
  23/May/2020

  	
   

  
	
  HK

  	
   

  	
  FPR1

  	
   

  	
  23/May/2000

  	
   

  	
  03102710.2

  	
   

  	
  27/Jun/2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  27/Jun/2003

  	
   

  	
  1050492 A

  	
   

  	
  23/May/2020

  	
   

  
	
  HU

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  P 0201640

  	
   

  	
  28/Aug/2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  28/Aug/2002

  	
   

  	
  P 0201640

  	
   

  	
  23/May/2020

  	
   

  
	
  IE

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  IT

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  LU

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  MC

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  MX

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  PA/A/2001/011998

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  23/Nov/2001

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  NL

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  20015745

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  26/Nov/2001

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  NZ

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  515147

  	
   

  	
  25/Jul/2003

  	
   

  	
  03/Nov/2003

  	
   

  	
  515147

  	
   

  	
  GRT

  	
   

  	
  03/Nov/2003

  	
   

  	
  515147

  	
   

  	
  23/May/2020

  	
   

  
	
  PL

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  P-351853

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  26/Nov/2001

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  PT

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  
	
  SE

  	
   

  	
  EPT1

  	
   

  	
  23/May/2000

  	
   

  	
  PCT/DE00/01678

  	
   

  	
  20/Feb/2002

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  GRT

  	
   

  	
  16/Jul/2003

  	
   

  	
  1180043

  	
   

  	
  23/May/2020

  	
   

  

 

A-8

 

	
  SK

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  PV 1691-2001

  	
   

  	
  04/Apr/2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  04/Apr/2002

  	
   

  	
   

  	
   

  	
  23/May/2020

  	
   

  
	
  US

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  09/979554

  	
   

  	
   

  	
   

  	
  25/Nov/2003

  	
   

  	
  6652782 B1

  	
   

  	
  GRT

  	
   

  	
  25/Nov/2003

  	
   

  	
  6652782 B1

  	
   

  	
  23/May/2020

  	
   

  
	
  ZA

  	
   

  	
  PCT1

  	
   

  	
  23/May/2000

  	
   

  	
  2001/10482

  	
   

  	
   

  	
   

  	
  25/Jun/2003

  	
   

  	
  2001/10482

  	
   

  	
  GRT

  	
   

  	
  25/Jun/2003

  	
   

  	
  2001/10482

  	
   

  	
  23/May/2020

  	
   

  

 

A-9

 

Patent
Family #52235A

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant

  number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  DE

  	
   

  	
  NP1

  	
   

  	
  28/Mar/2002

  	
   

  	
  10215335.3

  	
   

  	
  16/Oct/2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  16/Oct/2003

  	
   

  	
  DE 10215335 A1

  	
   

  	
  28/Mar/2022

  	
   

  
	
  EP

  	
   

  	
  EPT

  	
   

  	
  27/Mar/2003

  	
   

  	
  03745194.5

  	
   

  	
  22/Dec/2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  22/Dec/2004

  	
   

  	
  1487345

  	
   

  	
  27/Mar/2023

  	
   

  
	
  JP

  	
   

  	
  PCT

  	
   

  	
  27/Mar/2003

  	
   

  	
  2003-579664

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  28/Sep/2004

  	
   

  	
  2003-579664

  	
   

  	
  27/Mar/2023

  	
   

  
	
  US

  	
   

  	
  NP1

  	
   

  	
  28/Mar/2003

  	
   

  	
  10/400928

  	
   

  	
  13/May/2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PUB

  	
   

  	
  13/May/2004

  	
   

  	
  US-2004-0092820-A1

  	
   

  	
  28/Mar/2023

  	
   

  
	
  WO

  	
   

  	
  PCT

  	
   

  	
  27/Mar/2003

  	
   

  	
  PCT/EP03/03227

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  27/Mar/2003

  	
   

  	
  PCT/EP03/03227

  	
   

  	
   

  	
   

  

 

A-10

 

Appendix B

Third Party Rights under Ultrasound Patents; Other
Exceptions

 

1.)           Non-exclusive,
royalty-free, worldwide license under Ultrasound Patent EP 644 776 was granted
to Nycomed Imaging AS (now Amersham Health AS) (“Nycomed”) with the right to
sublicense to Affiliates under Settlement Agreement dated as of November 2,
1999 between Schering and Nycomed.

 

2.)           Non-exclusive
license under Ultrasound Patent EP 0744961 B1 was granted to Amersham Health AS
(“Amersham”) under Settlement and License Agreement dated as of October 8,
2004 between Schering and Amersham.

 

3.)           Non-exclusive
royalty free license under Ultrasound Patent EP 644777 was granted to Bracco
S.p.A. (“Bracco”) under Letter of Understanding dated as of November 14,
2000 between Schering and Bracco.

 

B-1

 

Appendix C

Harmonic Imaging Patents

 

Patent
Family #51172A1

 

	
   

  	
   

  	
  51172

  	
   

  	
  Licenses List

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant Number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AU

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  38424/95

  	
   

  	
  29/Oct/1998

  	
   

  	
  11/Feb/1999

  	
   

  	
  698398

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1999

  	
   

  	
  698398

  	
   

  	
  13/Oct/2015

  	
   

  
	
  CN

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  95195991.3

  	
   

  	
   

  	
   

  	
  23/Jun/2004

  	
   

  	
  159753

  	
   

  	
  GRT

  	
   

  	
  23/Jun/2004

  	
   

  	
  159753

  	
   

  	
  13/Oct/2015

  	
   

  
	
  IL

  	
   

  	
  NP1

  	
   

  	
  31/Oct/1995

  	
   

  	
  115832

  	
   

  	
  24/Aug/1997

  	
   

  	
  08/Mar/1999

  	
   

  	
  115832

  	
   

  	
  GRT

  	
   

  	
  08/Mar/1999

  	
   

  	
  115832

  	
   

  	
  31/Oct/2015

  	
   

  
	
  KR

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  10-1997-702870

  	
   

  	
  01/Dec/1997

  	
   

  	
  01/Apr/2003

  	
   

  	
  380126

  	
   

  	
  GRT

  	
   

  	
  01/Apr/2003

  	
   

  	
  380126

  	
   

  	
  13/Oct/2015

  	
   

  
	
  MX

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  972842

  	
   

  	
   

  	
   

  	
  18/Aug/2000

  	
   

  	
  198166

  	
   

  	
  GRT

  	
   

  	
  18/Aug/2000

  	
   

  	
  198166

  	
   

  	
  13/Oct/2015

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  972029

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  NATF

  	
   

  	
  30/Apr/1997

  	
   

  	
   

  	
   

  	
  13/Oct/2015

  	
   

  
	
  NZ

  	
   

  	
  PCT1

  	
   

  	
  13/Oct/1995

  	
   

  	
  295149

  	
   

  	
  28/Oct/1998

  	
   

  	
  10/Feb/1999

  	
   

  	
  295149

  	
   

  	
  GRT

  	
   

  	
  10/Feb/1999

  	
   

  	
  295149

  	
   

  	
  13/Oct/2015

  	
   

  
	
  TW

  	
   

  	
  NP1

  	
   

  	
  30/Nov/1995

  	
   

  	
  84112793

  	
   

  	
  21/Oct/1997

  	
   

  	
  11/Feb/1998

  	
   

  	
  NI-090114

  	
   

  	
  GRT

  	
   

  	
  11/Feb/1998

  	
   

  	
  NI-090114

  	
   

  	
  30/Nov/2015

  	
   

  
	
  US

  	
   

  	
  NP1

  	
   

  	
  01/Nov/1994

  	
   

  	
  08/332746

  	
   

  	
   

  	
   

  	
  21/Oct/1997

  	
   

  	
  5678553

  	
   

  	
  GRT

  	
   

  	
  21/Oct/1997

  	
   

  	
  5678553

  	
   

  	
  01/Nov/2014

  	
   

  
	
  ZA

  	
   

  	
  NP1

  	
   

  	
  31/Oct/1995

  	
   

  	
  95/9217

  	
   

  	
  31/Jul/1996

  	
   

  	
  31/Jul/1996

  	
   

  	
  95/9217

  	
   

  	
  GRT

  	
   

  	
  31/Jul/1996

  	
   

  	
  95/9217

  	
   

  	
  31/Oct/2015

  	
   

  

 

C-1

 

Patent Family #50107

 

	
   

  	
   

  	
  50107

  	
   

  	
  Licenses List

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

	
  Ctry

  	
   

  	
  Type

  	
   

  	
  Filing

  	
   

  	
  Filing Number

  	
   

  	
  Publication

  	
   

  	
  Grant

  	
   

  	
  Grant Number

  	
   

  	
  Proc

  	
   

  	
  Date

  	
   

  	
  Nature

  	
   

  	
  Exp

  	
   

  
	
  AT

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  E 68887

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  E 68887

  	
   

  	
  23/Aug/2009

  	
   

  
	
  AU

  	
   

  	
  PCT1

  	
   

  	
  23/Aug/1989

  	
   

  	
  41824/89

  	
   

  	
  20/May/1993

  	
   

  	
  13/Sep/1993

  	
   

  	
  637059

  	
   

  	
  GRT

  	
   

  	
  13/Sep/1993

  	
   

  	
  637059

  	
   

  	
  23/Aug/2009

  	
   

  
	
  BE

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  CA

  	
   

  	
  NP1

  	
   

  	
  31/Aug/1989

  	
   

  	
  610016

  	
   

  	
   

  	
   

  	
  19/Mar/1996

  	
   

  	
  1338175

  	
   

  	
  GRT

  	
   

  	
  19/Mar/1996

  	
   

  	
  1338175

  	
   

  	
  19/Mar/2013

  	
   

  
	
  CH

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  DE

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  P 58900401.8

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  P 58900401.8

  	
   

  	
  23/Aug/2009

  	
   

  
	
  DK

  	
   

  	
  PCT1

  	
   

  	
  23/Aug/1989

  	
   

  	
  316/91

  	
   

  	
  02/Jul/1993

  	
   

  	
  13/Dec/2004

  	
   

  	
  PR 175571

  	
   

  	
  GRT

  	
   

  	
  13/Dec/2004

  	
   

  	
  PR 175571

  	
   

  	
  23/Aug/2009

  	
   

  
	
  ES

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  FR

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  GB

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  GR

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  910401550

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  910401550

  	
   

  	
  23/Aug/2009

  	
   

  
	
  IT

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  JP

  	
   

  	
  PCT1

  	
   

  	
  23/Aug/1989

  	
   

  	
  1-508941

  	
   

  	
   

  	
   

  	
  25/Jul/1997

  	
   

  	
  2677888

  	
   

  	
  GRT

  	
   

  	
  25/Jul/1997

  	
   

  	
  2677888

  	
   

  	
  23/Aug/2009

  	
   

  
	
  KR

  	
   

  	
  PCT1

  	
   

  	
  23/Aug/1989

  	
   

  	
  700928/90

  	
   

  	
   

  	
   

  	
  23/Feb/1998

  	
   

  	
  138901

  	
   

  	
  GRT

  	
   

  	
  23/Feb/1998

  	
   

  	
  138901

  	
   

  	
  23/Aug/2009

  	
   

  
	
  LU

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  NL

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  0357164

  	
   

  	
  23/Aug/2009

  	
   

  
	
  NO

  	
   

  	
  PCT1

  	
   

  	
  23/Aug/1989

  	
   

  	
  910805

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  FLG

  	
   

  	
  23/Aug/1989

  	
   

  	
  910805

  	
   

  	
  23/Aug/2009

  	
   

  
	
  SE

  	
   

  	
  EPA1

  	
   

  	
  23/Aug/1989

  	
   

  	
  89250017.4

  	
   

  	
  07/Mar/1990

  	
   

  	
  23/Oct/1991

  	
   

  	
  89250017.4

  	
   

  	
  GRT

  	
   

  	
  23/Oct/1991

  	
   

  	
  89250017.4

  	
   

  	
  23/Aug/2009

  	
   

  
	
  TW

  	
   

  	
  NP1

  	
   

  	
  23/Oct/1989

  	
   

  	
  78108117

  	
   

  	
  01/Jan/1992

  	
   

  	
  14/Dec/1991

  	
   

  	
  NI-53209

  	
   

  	
  GRT

  	
   

  	
  14/Dec/1991

  	
   

  	
  NI-53209

  	
   

  	
  23/Oct/2009

  	
   

  
	
  US

  	
   

  	
  CWO1

  	
   

  	
  14/Jun/1993

  	
   

  	
  076221

  	
   

  	
   

  	
   

  	
  25/Apr/1995

  	
   

  	
  5410516

  	
   

  	
  GRT

  	
   

  	
  25/Apr/1995

  	
   

  	
  5410516

  	
   

  	
  25/Apr/2012

  	
   

  
	
  US

  	
   

  	
  CWO3

  	
   

  	
  06/Jun/1995

  	
   

  	
  08/467886

  	
   

  	
   

  	
   

  	
  16/May/2000

  	
   

  	
  6064628

  	
   

  	
  GRT

  	
   

  	
  16/May/2000

  	
   

  	
  6064628

  	
   

  	
   

  	
   

  
	
  US

  	
   

  	
  CWO4

  	
   

  	
  12/Jan/1999

  	
   

  	
  09/228972

  	
   

  	
   

  	
   

  	
  07/Mar/2000

  	
   

  	
  6034922

  	
   

  	
  GRT

  	
   

  	
  07/Mar/2000

  	
   

  	
  6034922

  	
   

  	
  23/Aug/2009

  	
   

  
	
  US

  	
   

  	
  CWO5

  	
   

  	
  02/Nov/1999

  	
   

  	
  09/432123

  	
   

  	
   

  	
   

  	
  24/Apr/2001

  	
   

  	
  6221017 B1

  	
   

  	
  GRT

  	
   

  	
  24/Apr/2001

  	
   

  	
  6221017 B1

  	
   

  	
  23/Aug/2009

  	
   

  
	
  US

  	
   

  	
  CWO6

  	
   

  	
  20/Dec/2000

  	
   

  	
  09/740054

  	
   

  	
   

  	
   

  	
  03/Sep/2002

  	
   

  	
  6443899 B2

  	
   

  	
  GRT

  	
   

  	
  03/Sep/2002

  	
   

  	
  6443899 B2

  	
   

  	
  23/Aug/2009

  	
   

  
	
  ZA

  	
   

  	
  NP1

  	
   

  	
  01/Sep/1989

  	
   

  	
  89/6738

  	
   

  	
   

  	
   

  	
  27/Jun/1990

  	
   

  	
  89/6738

  	
   

  	
  GRT

  	
   

  	
  27/Jun/1990

  	
   

  	
  89/6738

  	
   

  	
  01/Sep/2009

  	
   

  

 

C-2Exhibit 10.1

 

 

J.
L. HALSEY CORPORATION

2005 EQUITY-BASED COMPENSATION PLAN

 

 

TABLE OF CONTENTS

 

	
  1.

  	
   

  	
  Purpose

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  2.

  	
   

  	
  Definitions

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  3.

  	
   

  	
  Administration.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Authority of the Committee

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Manner of Exercise of Committee Authority

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Limitation of Liability

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  4.

  	
   

  	
  Stock Subject to Plan.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Overall Number of Shares Available for
  Delivery

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Application of Limitation to Grants of
  Awards

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Availability of Shares Not Delivered under
  Awards

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Stock Offered

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  5.

  	
   

  	
  Eligibility; Per Person Award Limitations

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  6.

  	
   

  	
  Specific Terms of Awards

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  General

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Options

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Stock Appreciation Rights

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Restricted Stock

  	
   

  
	
   

  	
   

  	
  (e)

  	
  Phantom Stock

  	
   

  
	
   

  	
   

  	
  (f)

  	
  Bonus Stock and Awards in Lieu of
  Obligations

  	
   

  
	
   

  	
   

  	
  (g)

  	
  Dividend Equivalents

  	
   

  
	
   

  	
   

  	
  (h)

  	
  Other Stock-Based Awards

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  7.

  	
   

  	
  Certain Provisions Applicable to Awards.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Stand-Alone, Additional, Tandem, and
  Substitute Awards

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Term of Awards

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Form and Timing of Payment under
  Awards; Deferrals

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Exemptions from
  Section 16(b) Liability

  	
   

  
	
   

  	
   

  	
  (e)

  	
  Non-Competition Agreement

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  8.

  	
   

  	
  Performance and Annual Incentive Awards.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Performance Conditions

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Performance Awards Granted to Designated
  Covered Employees

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Annual Incentive Awards Granted to
  Designated Covered Employees

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Written Determinations

  	
   

  
	
   

  	
   

  	
  (e)

  	
  Status of Section 8(b) and
  Section 8(c) Awards under Section 162(m) of the Code

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  9.

  	
   

  	
  Recapitalization or Reorganization.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Existence of Plans and Awards

  	
   

  

 

i

 

	
   

  	
   

  	
  (b)

  	
  Subdivision or Consolidation of Shares

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Corporate Restructuring

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Change in Control Price

  	
   

  
	
   

  	
   

  	
  (e)

  	
  Non-Option Awards

  	
   

  
	
   

  	
   

  	
  (f)

  	
  Additional Issuances

  	
   

  
	
   

  	
   

  	
  (g)

  	
  Restricted Stock Awards

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  10.

  	
   

  	
  General Provisions.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (a)

  	
  Transferability.

  	
   

  
	
   

  	
   

  	
  (b)

  	
  Taxes

  	
   

  
	
   

  	
   

  	
  (c)

  	
  Changes to this Plan and Awards

  	
   

  
	
   

  	
   

  	
  (d)

  	
  Limitation on Rights Conferred under Plan

  	
   

  
	
   

  	
   

  	
  (e)

  	
  Unfunded Status of Awards

  	
   

  
	
   

  	
   

  	
  (f)

  	
  Nonexclusivity of this Plan

  	
   

  
	
   

  	
   

  	
  (g)

  	
  Payments in the Event of Forfeitures;
  Fractional Shares

  	
   

  
	
   

  	
   

  	
  (h)

  	
  Severability

  	
   

  
	
   

  	
   

  	
  (i)

  	
  Governing Law

  	
   

  
	
   

  	
   

  	
  (j)

  	
  Conditions to Delivery of Stock

  	
   

  

 

ii

 

J. L. HALSEY CORPORATION

2005 EQUITY-BASED COMPENSATION PLAN

 

1.                                      Purpose.  The purpose of the J. L. Halsey Corporation
2005 Equity-Based Compensation Plan (the “Plan”) is to provide a means through
which J. L. Halsey Corporation, a Delaware corporation (the “Company”), and its
subsidiaries (including any companies it may acquire) may attract and retain
able persons as employees, directors and consultants of the Company and to
provide a means whereby those persons upon whom the responsibilities of the
successful administration and management of the Company rest, and whose present
and potential contributions to the welfare of the Company are of importance,
can acquire and maintain stock ownership, or awards the value of which is tied
to the performance of the Company’s stock, thereby strengthening their concern
for the welfare of the Company and their desire to remain in its employ.  A further purpose of this Plan is to provide
such employees and directors with additional incentive and reward opportunities
designed to enhance the profitable growth of the Company.  Accordingly, this Plan primarily provides for
granting Incentive Stock Options, options which do not constitute Incentive
Stock Options, Restricted Stock Awards, Stock Appreciation Rights, Phantom
Stock Awards or any combination of the foregoing, as is best suited to the
circumstances of the particular individual as provided herein.

 

2.                                      Definitions.  For purposes of this Plan, the following
terms shall be defined as set forth below, in addition to such terms defined in
Section 1 hereof:

 

(a)                                  “Annual
Incentive Award” means a conditional right granted to a Participant under Section 8(c) hereof
to receive a cash payment, Stock or other Award, unless otherwise determined by
the Committee, after the end of a specified fiscal year.

 

(b)                                 “Award”
means any Option, SAR (including Limited SAR), Restricted Stock Award, Phantom
Stock Award, Stock granted as a bonus or in lieu of another award, Dividend
Equivalent, Other Stock-Based Award, Performance Award or Annual Incentive
Award, together with any other right or interest granted to a Participant under
this Plan.

 

(c)                                  “Beneficiary”
means one or more persons, trusts or other entities which have been designated
by a Participant in his or her most recent written beneficiary designation
filed with the Committee to receive the benefits specified under this Plan upon
such Participant’s death or to which Awards or other rights are transferred if
and to the extent permitted under Section 10(a) hereof.  If, upon a Participant’s death, there is no
designated Beneficiary or surviving designated Beneficiary, then the term
Beneficiary means the persons, trusts or other entities entitled by will or the
laws of descent and distribution to receive such benefits.

 

(d)                                 “Beneficial
Owner” shall have the meaning ascribed to such term in Rule 13d-3
under the Exchange Act and any successor to such Rule.

 

(e)                                  “Board”
means the Company’s Board of Directors.

 

(f)                                    “Business
Day” means any day other than a Saturday, a Sunday, or a day on which banking
institutions in the state of Delaware are authorized or obligated by law or
executive order to close.

 

 

(g)                                 “Change
in Control” means the occurrence of any of the following events:

 

(i)                                     The
agreement to acquire or a tender offer that is accepted for beneficial
ownership (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) by any individual, entity or group (within the meaning of section 13(d)(3) or
14(d)(2) of the Exchange Act) (a “Person”), of 50% or more of either (x)
the then outstanding shares of Stock (the “Outstanding Stock”) or (y) the
combined voting power of the then outstanding voting securities of the Company
entitled to vote generally in the election of directors (the “Outstanding
Company Voting Securities”); provided, however, that for purposes of this subsection (i),
the following acquisitions shall not constitute a Change in Control:  (A) any acquisition directly from the
Company, (B) any acquisition by the Company, (C) any acquisition by
any employee benefit plan (or related trust) sponsored or maintained by the
Company or any corporation controlled by the Company, (D) any acquisition
by any corporation pursuant to a transaction which complies with clauses (A), (B) and
(C) of paragraph (iii) below; or

 

(ii)                                  Individuals
who constitute the Incumbent Board cease for any reason to constitute at least
a majority of the Board; or

 

(iii)                               Consummation
of a reorganization, merger or consolidation or sale or other disposition of
all or substantially all of the assets of the Company or an acquisition of
assets of another corporation (a “Business Combination”), in each case, unless,
following such Business Combination, (A) the Outstanding Stock and
Outstanding Company Voting Securities immediately prior to such Business
Combination represent or are converted into or exchanged for securities which
represent or are convertible into more than 50% of, respectively, the then
outstanding shares of common stock and the combined voting power of the then
outstanding voting securities entitled to vote generally in the election of
directors, as the case may be, of the corporation resulting from such Business
Combination (including, without limitation, a corporation which as a result of
such transaction owns the Company, or all or substantially all of the Company’s
assets either directly or through one or more subsidiaries), (B) no Person
(excluding any employee benefit plan (or related trust) of the Company or the
corporation resulting from such Business Combination) beneficially owns,
directly or indirectly, 20% or more of, respectively, the then outstanding
shares of common stock of the corporation resulting from such Business
Combination or the combined voting power of the then outstanding voting securities
of such corporation except to the extent that such ownership of the Company
existed prior to the Business Combination and (C) at least a majority of
the members of the board of directors of the corporation resulting from such
Business Combination were members of the Incumbent Board at the time of the
execution of the initial agreement, or of the action of the Board, providing
for such Business Combination; or

 

(iv)                              Consummation
of a reorganization, merger or consolidation or sale or other disposition of
all or substantially all of the assets of the Company (a “Business Combination”),
unless, following such Business Combination, the Outstanding Stock and
Outstanding Company Voting Securities immediately prior to such Business
Combination represent or are converted into or exchanged for securities which
represent or are convertible into more than 50% of, respectively, the then
outstanding shares of common stock and the combined voting power of the then
outstanding voting securities entitled to vote generally in the election of
directors, as the case may be, of the corporation resulting from such Business
Combination

 

2

 

(including, without limitation, a corporation which as a
result of such transaction owns the Company, or all or substantially all of the
Company’s assets either directly or through one or more subsidiaries); or

 

(v)                                 Approval
by the stockholders of the Company of a complete liquidation or dissolution of
the Company.

 

(h)                                 “Change
in Control Price” means the amount calculated in accordance with Section 9
of this Plan.

 

(i)                                     “Code”
means the Internal Revenue Code of 1986, as amended from time to time,
including regulations thereunder and successor provisions and regulations
thereto.

 

(j)                                     “Committee”
means a committee of two or more directors designated by the Board to
administer this Plan; provided, however, that, unless otherwise determined by
the Board, the Committee shall consist solely of two or more directors, each of
whom shall be (i) a “nonemployee director” within the meaning of Rule 16b-3
under the Exchange Act, and (ii) an “outside director” as defined under section 162(m)
of the Code, unless administration of this Plan by “outside directors” is not
then required in order to qualify for tax deductibility under section 162(m)
of the Code.

 

(k)                                  “Covered
Employee” means an Eligible Person who is a Covered Employee as specified in Section 8(e) of
this Plan.

 

(l)                                     “Dividend
Equivalent” means a right, granted to a Participant under Section 6(g), to
receive cash, Stock, other Awards or other property equal in value to dividends
paid with respect to a specified number of shares of Stock, or other periodic
payments.

 

(m)                               “Effective
Date” means May 6, 2005.

 

(n)                                 “Eligible
Person” means all officers and employees, or prospective officers and
employees, of the Company or of any Subsidiary, and other persons who provide
services to the Company or any of its Subsidiaries, including directors of the
Company.  An employee on leave of absence
may be considered as still in the employ of the Company or a Subsidiary for
purposes of eligibility for participation in this Plan.

 

(o)                                 “Exchange
Act” means the Securities Exchange Act of 1934, as amended from time to time,
including rules thereunder and successor provisions and rules thereto.

 

(p)                                 “Executive
Officer” means an executive officer of the Company as defined under the
Exchange Act.

 

(q)                                 “Fair
Market Value” means, for a particular day:

 

(i)                                     if
shares of Stock of the same class are listed or admitted to unlisted trading
privileges on any national or regional securities exchange at the date of
determining the Fair Market Value, then the last reported sale price, regular
way, on the composite tape of that exchange on that business day or, if no such
sale takes place on that

 

3

 

business day,
the average of the closing bid and asked prices, regular way, in either case as
reported in the principal consolidated transaction reporting system with
respect to securities listed or admitted to unlisted trading privileges on that
securities exchange or, if no such closing prices are available for that day,
the last reported sale price, regular way, on the composite tape of that
exchange on the last business day before the date in question; or

 

(ii)                                  if
shares of Stock of the same class are not listed or admitted to unlisted
trading privileges as provided in subparagraph (i) and if sales prices for
shares of Stock of the same class in the over-the-counter market are reported
by the OTC Bulletin Board (“OTCBB”) National Market System as of the date of
determining the Fair Market Value, then the last reported sales price so
reported on that business day or, if no such sale takes place on that business
day, the average of the high bid and low asked prices so reported or, if no
such prices are available for that day, the last reported sale price so
reported on the last business day before the date in question; or

 

(iii)                               if
shares of Stock of the same class are not listed or admitted to unlisted
trading privileges as provided in subparagraph (i) and sales prices for
shares of Stock of the same class are not reported by the OTCBB National Market System (or a similar
system then in use) as provided in subparagraph (ii), and if bid and asked
prices for shares of Stock of the same class in the over-the-counter market are
reported by OTCBB (or, if not so reported, by the National Quotation Bureau
Incorporated) as of the date of determining the Fair Market Value, then the
average of the high bid and low asked prices on that business day or, if no
such prices are available for that day, the average of the high bid and low
asked prices on the last business day before the date in question; or

 

(iv)                              if
shares of Stock of the same class are not listed or admitted to unlisted
trading privileges as provided in subparagraph (i) and sales prices or bid
and asked prices therefor are not reported by OTCBB (or the National Quotation
Bureau Incorporated) as provided in subparagraph (ii) or subparagraph (iii) as
of the date of determining the Fair Market Value, then the value determined in
good faith by the Committee, which determination shall be conclusive for all
purposes; or

 

(v)                                 if
shares of Stock of the same class are listed or admitted to unlisted trading
privileges as provided in subparagraph (i) or sales prices or bid and
asked prices therefor are reported by OTCBB (or the National Quotation Bureau
Incorporated) as provided in subparagraph (ii) or subparagraph (iii) as
of the date of determining the Fair Market Value, but the volume of trading is
so low that the Board of Directors determines in good faith that such prices
are not indicative of the fair value of the Stock, then the value determined in
good faith by the Committee, which determination shall be conclusive for all
purposes notwithstanding the provisions of subparagraphs (i), (ii) or
(iii).

 

For purposes
of valuing Incentive Stock Options, the Fair Market Value of Stock shall be
determined without regard to any restriction other than one that, by its terms,
will never lapse.

 

(r)                                    “Incentive
Stock Option” or “ISO” means any Option intended to be and designated as an
incentive stock option within the meaning of section 422 of the Code or
any successor provision thereto.

 

4

 

(s)                                  “Incumbent
Board” shall mean individuals who constitute the Board as of the Effective Date
and any other individual who becomes a director of the Company after that date
and whose election or appointment by the Board or nomination for election by
the Company’s stockholders was approved by a vote of at least a majority of the
directors then comprising the Incumbent Board, but excluding, for this purpose,
any such individual whose initial assumption of office occurs as a result of an
actual or threatened election contest with respect to the election or removal
of directors or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Incumbent Board.

 

(t)                                    “Limited
SAR” means a right granted to a Participant under Section 6(c) hereof.

 

(u)                                 “Option”
means a right, granted to a Participant under Section 6(b) hereof, to
purchase Stock or other Awards at a specified price during specified time
periods.

 

(v)                                 “Other
Stock-Based Awards” means Awards granted to a Participant under Section 6(h) hereof.

 

(w)                               “Participant”
means a person who has been granted an Award under this Plan which remains
outstanding, including a person who is no longer an Eligible Person.

 

(x)                                   “Performance
Award” means a right, granted to a Participant under Section 8 hereof, to
receive Awards based upon performance criteria specified by the Committee.

 

(y)                                 “Person”
means any person or entity of any nature whatsoever, specifically including an
individual, a firm, a company, a corporation, a partnership, a limited
liability company, a trust or other entity; a Person, together with that Person’s
Affiliates and Associates (as those terms are defined in Rule 12b-2
under the Exchange Act), and any Persons acting as a partnership, limited
partnership, joint venture, association, syndicate or other group (whether or
not formally organized), or otherwise acting jointly or in concert or in a
coordinated or consciously parallel manner (whether or not pursuant to any
express agreement), for the purpose of acquiring, holding, voting or disposing
of securities of the Company with such Person, shall be deemed a single “Person.”

 

(z)                                   “Phantom
Stock” means a right, granted to a Participant under Section 6(e) hereof,
to receive Stock, cash or a combination thereof at the end of a specified
deferral period.

 

(aa)                            “Qualified
Member” means a member of the Committee who is a “Non-Employee Director” within
the meaning of Rule 16b-3(b)(3) and an
“outside director” within the meaning of regulation 1.162-27 under section 162(m)
of the Code.

 

(bb)                          “Restricted
Stock” means Stock granted to a Participant under Section 6(d) hereof,
that is subject to certain restrictions and to a risk of forfeiture.

 

(cc)                            “Rule 16b-3”
means Rule 16b-3, promulgated by the Securities and Exchange
Commission under section 16 of the Exchange Act, as from time to time in
effect and applicable to this Plan and Participants.

 

5

 

(dd)                          “Securities
Act” means the Securities Act of 1933 and the rules and regulations
promulgated thereunder, or any successor law, as it may be amended from time to
time.

 

(ee)                            “Stock”
means the Company’s Common Stock, par value $.01 per share, and such other
securities as may be substituted (or resubstituted) for Stock pursuant to Section 9.

 

(ff)                                “Stock
Appreciation Rights” or “SAR” means a right granted to a Participant under Section 6(c) hereof.

 

(gg)                          “Subsidiary”
means with respect to any Person, any corporation or other entity of which a
majority of the voting power of the voting equity securities or equity interest
is owned, directly or indirectly, by that Person.

 

3.                                      Administration.

 

(a)                                  Authority of the Committee.  This Plan shall be administered by the
Committee except to the extent the Board elects, in order to comply with Rule 16b-3
or for any other reason, to administer this Plan, in which case references
herein to the “Committee” shall be deemed to include references to the “Board.”  Subject to the express provisions of the Plan
and Rule 16b-3, the Committee shall have the authority, in its sole
and absolute discretion, to (i) adopt, amend, and rescind administrative
and interpretive rules and regulations relating to the Plan; (ii) determine
the Eligible Persons to whom, and the time or times at which, Awards shall be
granted; (iii) determine the amount of cash and the number of shares of
Stock, Stock Appreciation Rights, Phantom Stock Rights, or Restricted Stock
Awards, or any combination thereof, that shall be the subject of each Award; (iv) determine
the terms and provisions of each Award agreement (which need not be identical),
including provisions defining or otherwise relating to (A) the term and
the period or periods and extent of exercisability of the Options, (B) the
extent to which the transferability of shares of Stock issued or transferred
pursuant to any Award is restricted, (C) the effect of termination of
employment of a Participant on the Award, and (D) the effect of approved
leaves of absence (consistent with any applicable regulations of the Internal
Revenue Service); (v) accelerate the time of exercisability of any Option
that has been granted; (vi) construe the respective Award agreements and
the Plan; (vii) make determinations of the Fair Market Value of the Stock
pursuant to the Plan; (viii) delegate its duties under the Plan to such
agents as it may appoint from time to time, provided that the Committee may not
delegate its duties with respect to making Awards to, or otherwise with respect
to Awards granted to, Eligible Persons who are subject to section 16(b) of
the Exchange Act or section 162(m) of the Code; (ix) subject to
ratification by the Board, terminate, modify, or amend the Plan; and (x) make
all other determinations, perform all other acts, and exercise all other powers
and authority necessary or advisable for administering the Plan, including the
delegation of those ministerial acts and responsibilities as the Committee
deems appropriate.  Subject to Rule 16b-3
and section 162(m) of the Code, the Committee may correct any defect,
supply any omission, or reconcile any inconsistency in the Plan, in any Award,
or in any Award agreement in the manner and to the extent it deems necessary or
desirable to carry the Plan into effect, and the Committee shall be the sole
and final judge of that necessity or desirability.  The determinations of the Committee on the
matters referred to in this Section 3(a) shall be final and
conclusive.

 

6

 

(b)                                 Manner of Exercise of
Committee Authority.  At any time that a member of the Committee is
not a Qualified Member, any action of the Committee relating to an Award
granted or to be granted to a Participant who is then subject to section 16
of the Exchange Act in respect of the Company, or relating to an Award intended
by the Committee to qualify as “performance-based compensation” within the
meaning of section 162(m) of the Code and regulations thereunder, may be
taken either (i) by a subcommittee, designated by the Committee, composed
solely of two or more Qualified Members, or (ii) by the Committee but with
each such member who is not a Qualified Member abstaining or recusing himself
or herself from such action; provided, however, that, upon such abstention or
recusal, the Committee remains composed solely of two or more Qualified
Members.  Such action, authorized by such
a subcommittee or by the Committee upon the abstention or recusal of such
non-Qualified Member(s), shall be the action of the Committee for purposes of
this Plan.  Any action of the Committee
shall be final, conclusive and binding on all persons, including the Company,
its subsidiaries, stockholders, Participants, Beneficiaries, and transferees
under Section 10(a) hereof or other persons claiming rights from or
through a Participant.  The express grant
of any specific power to the Committee, and the taking of any action by the
Committee, shall not be construed as limiting any power or authority of the
Committee.  The Committee may delegate to
officers or managers of the Company or any Subsidiary, or committees thereof,
the authority, subject to such terms as the Committee shall determine, to
perform such functions, including administrative functions, as the Committee
may determine, to the extent that such delegation will not result in the loss
of an exemption under Rule 16b-3(d)(1) for Awards granted to
Participants subject to section 16 of the Exchange Act in respect of the
Company and will not cause Awards intended to qualify as “performance-based
compensation” under section 162(m) of the Code to fail to so qualify.  The Committee may appoint agents to assist it
in administering this Plan.

 

(c)                                  Limitation of Liability.  The Committee and each member thereof shall
be entitled to, in good faith, rely or act upon any report or other information
furnished to him or her by any officer or employee of the Company or a
Subsidiary, the Company’s legal counsel, independent auditors, consultants or
any other agents assisting in the administration of this Plan.  Members of the Committee and any officer or
employee of the Company or a Subsidiary acting at the direction or on behalf of
the Committee shall not be personally liable for any action or determination
taken or made in good faith with respect to this Plan, and shall, to the
fullest extent permitted by law, be indemnified and held harmless by the
Company with respect to any such action or determination.

 

4.                                      Stock Subject to Plan.

 

(a)                                  Overall Number of Shares
Available for Delivery.  Subject to adjustment in a manner consistent
with any adjustment made pursuant to Section 9, the total number of shares
of Stock reserved and available for delivery in connection with Awards under
this Plan shall not exceed 13,200,000 shares.

 

(b)                                 Application of Limitation to
Grants of Awards.  No Award may
be granted if (i) the number of shares of Stock to be delivered in
connection with such Award  exceeds (ii) the
number of shares of Stock remaining available under this Plan minus the number
of shares of Stock issuable in settlement of or relating to then-outstanding Awards.  The Committee may adopt reasonable counting
procedures to ensure appropriate counting, avoid

 

7

 

double counting (as, for example, in the
case of tandem or substitute awards) and make adjustments if the number of
shares of Stock actually delivered differs from the number of shares previously
counted in connection with an Award.

 

(c)                                  Availability of Shares Not
Delivered under Awards.  Shares of Stock subject to an Award under
this Plan that expire or are canceled, forfeited, settled in cash or otherwise
terminated without a delivery of shares to the Participant, including (i) the
number of shares withheld in payment of any exercise or purchase price of an
Award or taxes relating to Awards, and (ii) the number of shares
surrendered in payment of any exercise or purchase price of an Award or taxes
relating to any Award, will again be available for Awards under this Plan,
except that if any such shares could not again be available for Awards to a
particular Participant under any applicable law or regulation, such shares
shall be available exclusively for Awards to Participants who are not subject
to such limitation.

 

(d)                                 Stock Offered.  The shares to be delivered under the Plan
shall be made available from (i) authorized but unissued shares of Stock, (ii) Stock
held in the treasury of the Company, or (iii) previously issued shares of
Stock reacquired by the Company, including shares purchased on the open market,
in each situation as the Board or the Committee may determine from time to time
at its sole option.

 

5.                                      Eligibility; Per Person Award
Limitations.  Awards may be granted under this Plan only to
Eligible Persons.  In each fiscal year or
12-month period, as applicable, during any part of which this Plan is in
effect, a Covered Employee may not be granted (a) Awards relating to more
than 6,000,000 shares of Stock, subject to adjustment in a manner consistent
with any adjustment made pursuant to Section 9 or (b) in the case of
Awards not related to shares of Stock Awards with a value at the time of
payment in excess of $5,000,000.

 

6.                                      Specific Terms of Awards.

 

(a)                                  General. 
Awards may be granted on the terms and conditions set forth in this Section 6.  In addition, the Committee may impose on any
Award or the exercise thereof, at the date of grant or thereafter (subject to Section 10(c)),
such additional terms and conditions, not inconsistent with the provisions of
this Plan, as the Committee shall determine, including terms requiring
forfeiture of Awards in the event of termination of employment by the
Participant and terms permitting a Participant to make elections relating to
his or her Award.  The Committee shall
retain full power and discretion to accelerate, waive or modify, at any time,
any term or condition of an Award that is not mandatory under this Plan;
provided, however, that the Committee shall not have any discretion to
accelerate, waive or modify any term or condition of an Award that is intended
to qualify as “performance-based compensation” for purposes of section 162(m)
of the Code if such discretion would cause the Award to not so qualify.  Except in cases in which the Committee is
authorized to require other forms of consideration under this Plan, or to the
extent other forms of consideration must be paid to satisfy the requirements of
the Delaware General Corporation Law, no consideration other than services may
be required for the grant (but not the exercise) of any Award.

 

(b)                                 Options.  The Committee is authorized to grant Options
to Participants on the following terms and conditions:

 

8

 

(i)                                     Exercise
Price.  Each Option agreement shall
state the exercise price per share of Stock (the “Exercise Price”); provided,
however, that the Exercise Price per share of Stock subject to an Incentive
Stock Option shall not be less than the greater of (A) the par value per
share of the Stock or (B) 100% of the Fair Market Value per share of the
Stock on the date of grant of the Option or in the case of an individual who
owns stock possessing more than 10 percent of the total combined voting power
of all classes of stock of the Corporation or its parent or any Subsidiary 110%
of the Fair Market Value per share of the Stock on the date of grant, and the
exercise price per share of Stock subject to an Option other than an Incentive
Stock Option shall not be less than the par value per share of the Stock (but
may be less than the Fair Market Value of a share of the Stock on the date of
grant).

 

(ii)                                  Time
and Method of Exercise.  The
Committee shall determine the time or times at which or the circumstances under
which an Option may be exercised in whole or in part (including based on
achievement of performance goals and/or future service requirements), the
methods by which such exercise price may be paid or deemed to be paid, the form
of such payment, including without limitation cash, Stock, other Awards or
awards granted under other plans of the Company or any Subsidiary, or other
property (including notes or other contractual obligations of Participants to
make payment on a deferred basis), and the methods by or forms in which Stock
will be delivered or deemed to be delivered to Participants, including, but not
limited to, the delivery of Restricted Stock subject to Section 6(d).  In the case of an exercise whereby the
Exercise Price is paid with Stock, such Stock shall be valued as of the date of
exercise.

 

(iii)                               ISOs.  The terms of any ISO granted under this Plan
shall comply in all respects with the provisions of section 422 of the
Code.  Anything in this Plan to the
contrary notwithstanding, no term of this Plan relating to ISOs (including any
SAR in tandem therewith) shall be interpreted, amended or altered, nor shall
any discretion or authority granted under this Plan be exercised, so as to
disqualify either this Plan or any ISO under section 422 of the Code,
unless the Participant has first requested the change that will result in such
disqualification.  ISOs shall not be
granted more than ten years after the earlier of the adoption of this Plan or
the approval of this Plan by the Company’s stockholders.  Notwithstanding the foregoing, the Fair
Market Value of shares of Stock subject to an ISO and the aggregate Fair Market
Value of shares of stock of any parent or Subsidiary corporation (within the
meaning of sections 424(e) and (f) of the Code) subject to any other
incentive stock option (within the meaning of section 422 of the Code)) of
the Company or a parent or Subsidiary corporation (within the meaning of sections
424(e) and (f) of the Code) that first becomes purchasable by a
Participant in any calendar year may not (with respect to that Participant)
exceed $100,000, or such other amount as may be prescribed under section 422
of the Code or applicable regulations or rulings from time to time.  As used in the previous sentence, Fair Market
Value shall be determined as of the date the incentive stock options
is granted.  Failure to comply
with this provision shall not impair the enforceability or exercisability of
any Option, but shall cause the excess amount of shares to be reclassified in
accordance with the Code.

 

(c)                                  Stock Appreciation Rights.  The Committee is authorized to grant SARs to
Participants on the following terms and conditions:

 

9

 

(i)                                     Right
to Payment.  An SAR shall confer on
the Participant to whom it is granted a right to receive, upon exercise or
settlement thereof, the excess of (A) the Fair Market Value of one share
of Stock on the date of exercise or settlement (or, in the case of a “Limited
SAR,” the Fair Market Value determined by reference to the Change in Control
Price, as defined under Section 2(h) hereof) over (B) the grant
price of the SAR as determined by the Committee.

 

(ii)                                  Rights
Related to Options.  A Stock
Appreciation Right granted pursuant to an Option shall entitle a Participant,
upon exercise or settlement, to surrender that Option or any portion thereof,
to the extent unexercised or not settled, and to receive payment of an amount
computed pursuant to Subsection 6(c)(ii)(B).  That Option shall then cease to be
exercisable or settleable to the extent surrendered.  Stock Appreciation Rights granted in
connection with an Option shall be subject to the terms of the Award agreement
governing the Option, which shall comply with the following provisions in
addition to those applicable to Options:

 

(A)                              A
Stock Appreciation Right granted in connection with an Option shall be
exercisable or settleable only at such time or times and only to the extent
that the related Option is exercisable and shall not be transferable except to
the extent that the related Option is transferable.

 

(B)                                Upon
the exercise or settlement of a Stock Appreciation Right related to an Option,
a Participant shall be entitled to receive payment from the Company of an
amount determined by multiplying:

 

(1)                                  the difference obtained by subtracting the exercise price of
a share of Stock specified in the related Option from the Fair Market Value of
a share of Stock on the date of exercise or settlement of the Stock
Appreciation Right, by

 

(2)                                  the number of shares as to which that Stock Appreciation
Right has been exercised or settled.

 

(iii)                               Right
Without Option. 
A Stock Appreciation Right granted independent of an Option shall be
exercisable or settleable as determined by the Committee and set forth in the
Award agreement governing the Stock Appreciation Right, which Award agreement
shall comply with the following provisions:

 

(A)                              Each
Award agreement shall state the total number of shares of Stock to which the
Stock Appreciation Right relates.

 

(B)                                Each
Award agreement shall state the time at which the Stock Appreciation Right will
vest, the time the Stock Appreciation Right will be settled, or the time or
periods in which the right to exercise the Stock Appreciation Right or a
portion thereof shall vest and the number of shares of Stock for which the
right to exercise the Stock Appreciation Right shall vest at each such time or
period.

 

10

 

(C)                                Each
Award agreement shall state the date at which the Stock Appreciation Rights
shall expire if not previously exercised or settled.

 

(D)                               Each
Stock Appreciation Right shall entitle a Participant, upon exercise or
settlement thereof, to receive payment of an amount determined by multiplying:

 

(1)                                  the
difference obtained by subtracting the Fair Market Value of a share of Stock on
the date of grant of the Stock Appreciation Right from the Fair Market Value of
a share of Stock on the date of exercise or settlement of that Stock
Appreciation Right, by

 

(2)                                  the number of shares as to which the Stock Appreciation
Right has been exercised or settled.

 

(iv)                              Terms.  The Committee shall determine at the date of
grant or thereafter, the time or times at which and the circumstances under
which an SAR may be exercised or settled in whole or in part (including based
on achievement of performance goals and/or future service requirements), the
method of exercise, method of settlement, form of consideration payable in
settlement, method by or forms in which Stock will be delivered or deemed to be
delivered to Participants, whether or not an SAR shall be in tandem or in
combination with any other Award, and any other terms and conditions of any
SAR.  Limited SARs that may only be
exercised in connection with a Change in Control or other event as specified by
the Committee may be granted on such terms, not inconsistent with this Section 6(c),
as the Committee may determine.  SARs and
Limited SARs may be either freestanding or in tandem with other Awards.

 

(d)                                 Restricted Stock.  The Committee is authorized to grant
Restricted Stock to Participants on the following terms and conditions:

 

(i)                                     Grant
and Restrictions.  Restricted Stock
shall be subject to such restrictions on transferability, risk of forfeiture
and other restrictions, if any, as the Committee may impose, which restrictions
may lapse separately or in combination at such times, under such circumstances
(including based on achievement of performance goals and/or future service
requirements), in such installments or otherwise, as the Committee may
determine at the date of grant or thereafter. 
Except to the extent restricted under the terms of this Plan and any
Award agreement relating to the Restricted Stock, a Participant granted
Restricted Stock shall have all of the rights of a stockholder, including the
right to vote the Restricted Stock and the right to receive dividends thereon
(subject to any mandatory reinvestment or other requirement imposed by the
Committee).  During the restricted period
applicable to the Restricted Stock, the Restricted Stock may not be sold,
transferred, pledged, hypothecated, margined or otherwise encumbered by the
Participant.

 

(ii)                                  Forfeiture.  Except as otherwise determined by the
Committee, upon termination of employment during the applicable restriction
period, Restricted Stock that is at that time subject to restrictions shall be
forfeited and reacquired by the Company; provided that the Committee may
provide, by rule or regulation or in any Award agreement, or may

 

11

 

determine in any individual
case, that restrictions or forfeiture conditions relating to Restricted Stock
shall be waived in whole or in part in the event of terminations resulting from
specified causes, and the Committee may in other cases waive in whole or in
part the forfeiture of Restricted Stock.

 

(iii)                               Certificates
for Stock.  Restricted Stock granted
under this Plan may be evidenced in such manner as the Committee shall
determine.  If certificates representing
Restricted Stock are registered in the name of the Participant, the Committee
may require that such certificates bear an appropriate legend referring to the terms,
conditions and restrictions applicable to such Restricted Stock, that the
Company retain physical possession of the certificates, and that the
Participant deliver a stock power to the Company, endorsed in blank, relating
to the Restricted Stock.

 

(iv)                              Dividends
and Splits.  As a condition to the
grant of an Award of Restricted Stock, the Committee may require or permit a
Participant to elect that any cash dividends paid on a share of Restricted
Stock be automatically reinvested in additional shares of Restricted Stock or
applied to the purchase of additional Awards under this Plan.  Unless otherwise determined by the Committee,
Stock distributed in connection with a Stock split or Stock dividend, and other
property distributed as a dividend, shall be subject to restrictions and a risk
of forfeiture to the same extent as the Restricted Stock with respect to which
such Stock or other property has been distributed.

 

(e)                                  Phantom Stock.  The Committee is authorized to grant Phantom
Stock to Participants, which are rights to receive Stock, cash, or a
combination thereof at the end of a specified deferral period, subject to the
following terms and conditions:

 

(i)                                     Award
and Restrictions.  Satisfaction of an
Award of Phantom Stock shall occur upon expiration of the deferral period
specified for such Phantom Stock by the Committee (or, if permitted by the
Committee, as elected by the Participant). 
In addition, Phantom Stock shall be subject to such restrictions (which
may include a risk of forfeiture) as the Committee may impose, if any, which
restrictions may lapse at the expiration of the deferral period or at earlier
specified times (including based on achievement of performance goals and/or
future service requirements), separately or in combination, in installments or
otherwise, as the Committee may determine. 
Phantom Stock may be satisfied by delivery of Stock, cash equal to the
Fair Market Value of the specified number of shares of Stock covered by the
Phantom Stock, or a combination thereof, as determined by the Committee at the
date of grant or thereafter.

 

(ii)                                  Forfeiture.  Except as otherwise determined by the
Committee, upon termination of employment during the applicable deferral period
or portion thereof to which forfeiture conditions apply (as provided in the
Award agreement evidencing the Phantom Stock), all Phantom Stock that is at
that time subject to deferral (other than a deferral at the election of the
Participant) shall be forfeited; provided that the Committee may provide, by rule or
regulation or in any Award agreement, or may determine in any individual case,
that restrictions or forfeiture conditions relating to Phantom Stock shall be
waived in whole or in part in the event of terminations resulting from
specified causes, and the Committee may in other cases waive in whole or in part
the forfeiture of Phantom Stock.

 

12

 

(iii)                               Dividend
Equivalents.  Unless otherwise
determined by the Committee at date of grant, Dividend Equivalents on the
specified number of shares of Stock covered by an Award of Phantom Stock shall
be either (A) paid with respect to such Phantom Stock on the dividend
payment date in cash or in shares of unrestricted Stock having a Fair Market
Value equal to the amount of such dividends, or (B) deferred with respect
to such Phantom Stock and the amount or value thereof automatically deemed
reinvested in additional Phantom Stock, other Awards or other investment
vehicles, as the Committee shall determine or permit the Participant to elect.

 

(f)                                    Bonus Stock and Awards in Lieu
of Obligations.  The Committee is
authorized to grant Stock as a bonus, or to grant Stock or other Awards in lieu
of obligations to pay cash or deliver other property under this Plan or under
other plans or compensatory arrangements, provided that, in the case of
Participants subject to section 16 of the Exchange Act, the amount of such
grants remains within the discretion of the Committee to the extent necessary
to ensure that acquisitions of Stock or other Awards are exempt from liability
under section 16(b) of the Exchange Act.  Stock or Awards granted hereunder shall be
subject to such other terms as shall be determined by the Committee.  In the case of any grant of Stock to an officer
of the Company or a Subsidiary in lieu of salary or other cash compensation,
the number of shares granted in place of such compensation shall be reasonable,
as determined by the Committee.

 

(g)                                 Dividend Equivalents.  The Committee is authorized to grant Dividend
Equivalents to a Participant, entitling the Participant to receive cash, Stock,
other Awards, or other property equal in value to dividends paid with respect
to a specified number of shares of Stock, or other periodic payments.  Dividend Equivalents may be awarded on a free-standing
basis or in connection with another Award. 
The Committee may provide that Dividend Equivalents shall be paid or
distributed when accrued or shall be deemed to have been reinvested in
additional Stock, Awards, or other investment vehicles, and subject to such
restrictions on transferability and risks of forfeiture, as the Committee may
specify.

 

(h)                                 Other Stock-Based Awards.  The Committee is authorized, subject to
limitations under applicable law, to grant to Participants such other Awards
that may be denominated or payable in, valued in whole or in part by reference
to, or otherwise based on, or related to, Stock, as deemed by the Committee to
be consistent with the purposes of this Plan, including without limitation
convertible or exchangeable debt securities, other rights convertible or
exchangeable into Stock, purchase rights for Stock, Awards with value and
payment contingent upon performance of the Company or any other factors
designated by the Committee, and Awards valued by reference to the book value
of Stock or the value of securities of or the performance of specified
subsidiaries.  The Committee shall
determine the terms and conditions of such Awards.  Stock delivered pursuant to an Award in the
nature of a purchase right granted under this Section 6(h) shall be
purchased for such consideration, paid for at such times, by such methods, and
in such forms, including, without limitation, cash, Stock, other Awards, or
other property, as the Committee shall determine.  Cash awards, as an element of or supplement
to any other Award under this Plan, may also be granted pursuant to this Section 6(h).

 

13

 

7.                                      Certain Provisions Applicable
to Awards.

 

(a)                                  Stand-Alone, Additional,
Tandem, and Substitute Awards. 
Awards granted under this Plan may, in the discretion of the Committee,
be granted either alone or in addition to, in tandem with, or in substitution
or exchange for, any other Award or any award granted under another plan of the
Company, any Subsidiary, or any business entity to be acquired by the Company
or a Subsidiary, or any other right of a Participant to receive payment from
the Company or any Subsidiary.  Such
additional, tandem and substitute or exchange Awards may be granted at any time.  If an Award is granted in substitution or
exchange for another Award, the Committee shall require the surrender of such
other Award in consideration for the grant of the new Award.  In addition, Awards may be granted in lieu of
cash compensation, including in lieu of cash amounts payable under other plans
of the Company or any Subsidiary, in which the value of Stock subject to the
Award is equivalent in value to the cash compensation (for example, Phantom
Stock or Restricted Stock), or in which the exercise price, grant price or
purchase price of the Award in the nature of a right that may be exercised is
equal to the Fair Market Value of the underlying Stock minus the value of the
cash compensation surrendered (for example, Options granted with an exercise
price “discounted” by the amount of the cash compensation surrendered).

 

(b)                                 Term of Awards.  The term of each Award shall be for such
period as may be determined by the Committee; provided that in no event shall
the term of any Option or SAR exceed a period of ten years (or such shorter
term as may be required in respect of an ISO under section 422 of the
Code).

 

(c)                                  Form and Timing of
Payment under Awards; Deferrals. 
Subject to the terms of this Plan and any applicable Award agreement,
payments to be made by the Company or a Subsidiary upon the exercise of an
Option or other Award or settlement of an Award may be made in such forms as
the Committee shall determine, including without limitation cash, Stock, other
Awards or other property, and may be made in a single payment or transfer, in installments,
or on a deferred basis.  The settlement
of any Award may be accelerated, and cash paid in lieu of Stock in connection
with such settlement, in the discretion of the Committee or upon occurrence of
one or more specified events (in addition to a Change in Control).  Installment or deferred payments may be
required by the Committee (subject to Section 10(c) of this Plan,
including the consent provisions thereof in the case of any deferral of an
outstanding Award not provided for in the original Award agreement) or
permitted at the election of the Participant on terms and conditions
established by the Committee.  Payments
may include, without limitation, provisions for the payment or crediting of
reasonable interest on installment or deferred payments or the grant or
crediting of Dividend Equivalents or other amounts in respect of installment or
deferred payments denominated in Stock. 
Any deferral shall only be allowed as is provided in a separate deferred
compensation plan adopted by the Company. 
This Plan shall not constitute an “employee benefit plan” for purposes
of section 3(3) of the Employee Retirement Income Security Act of
1974, as amended.

 

(d)                                 Exemptions from Section 16(b) Liability.  It is the intent of the Company that the
grant of any Awards to or other transaction by a Participant who is subject to section 16
of the Exchange Act shall be exempt from section 16 pursuant to an
applicable exemption (except for transactions acknowledged in writing to be
non-exempt by such Participant).

 

14

 

Accordingly, if any provision
of this Plan or any Award agreement does not comply with the requirements of Rule 16b-3
as then applicable to any such transaction, such provision shall be construed
or deemed amended to the extent necessary to conform to the applicable
requirements of Rule 16b-3 so that such Participant shall avoid
liability under section 16(b).

 

(e)                                  Non-Competition Agreement.  Each Participant to whom an Award is granted
under this Plan may be required to agree in writing as a condition to the
granting of such Award not to engage in conduct in competition with the Company
or any of its subsidiaries for a period after the termination of such
Participant’s employment with the Company and its subsidiaries as determined by
the Committee.

 

8.                                      Performance and Annual
Incentive Awards.

 

(a)                                  Performance Conditions.  The right of a Participant to exercise or
receive a grant or settlement of any Award, and the timing thereof, may be
subject to such performance conditions as may be specified by the
Committee.  The Committee may use such
business criteria and other measures of performance as it may deem appropriate
in establishing any performance conditions, and may exercise its discretion to
reduce or increase the amounts payable under any Award subject to performance
conditions, except as limited under Sections 8(b) and 8(c) hereof in
the case of a Performance Award or Annual Incentive Award intended to qualify
under section 162(m) of the Code.

 

(b)                                 Performance Awards Granted
to Designated Covered Employees. 
If the Committee determines that a Performance Award to be granted to an
Eligible Person who is designated by the Committee as likely to be a Covered
Employee should qualify as “performance-based compensation” for purposes of section 162(m)
of the Code, the grant, exercise and/or settlement of such Performance Award
may be contingent upon achievement of preestablished performance goals and
other terms set forth in this Section 8(b).

 

(i)                                     Performance
Goals Generally.  The performance
goals for such Performance Awards shall consist of one or more business
criteria or individual performance criteria and a targeted level or levels of
performance with respect to each of such criteria, as specified by the Committee
consistent with this Section 8(b). 
Performance goals shall be objective and shall otherwise meet the
requirements of section 162(m) of the Code and regulations thereunder
(including Treasury Regulation §1.162-27 and successor regulations
thereto), including the requirement that the level or levels of performance
targeted by the Committee result in the achievement of performance goals being “substantially
uncertain.”  The Committee may determine
that such Performance Awards shall be granted, exercised, and/or settled upon
achievement of any one performance goal or that two or more of the performance
goals must be achieved as a condition to grant, exercise and/or settlement of
such Performance Awards.  Performance goals
may differ for Performance Awards granted to any one Participant or to
different Participants.

 

(ii)                                  Business
and Individual Performance Criteria

 

(A)                              Business
Criteria.  One or more of the
following business criteria for the Company, on a consolidated basis, and/or
for specified subsidiaries or

 

15

 

business or
geographical units of the Company (except with respect to the total stockholder
return and earnings per share criteria), shall be used by the Committee in
establishing performance goals for such Performance Awards:  (1) earnings per share; (2) increase
in revenues; (3) increase in cash flow; (4) increase in cash flow
return; (5) return on net assets, return on assets, return on investment,
return on capital, or return on equity; (6) economic value added; (7) operating
margin or contribution margin; (8) net income; pretax earnings; pretax
earnings before interest, depreciation and amortization; pretax operating
earnings after interest expense and before incentives, service fees, and
extraordinary or special items; or operating income; (9) total stockholder
return; (10) debt reduction; and (11) any of the above goals determined on
an absolute or relative basis or as compared to the performance of a published
or special index deemed applicable by the Committee including, but not limited
to, the Standard & Poor’s 500 Stock Index or a group of comparable
companies.  One or more of the foregoing
business criteria shall also be exclusively used in establishing performance
goals for Annual Incentive Awards granted to a Covered Employee under Section 8(c) hereof.

 

(B)                                Individual
Performance Criteria.  The grant,
exercise and/or settlement of Performance Awards may also be contingent upon
individual performance goals established by the Committee.  If required for compliance with section 162(m)
of the Code, such criteria shall be approved by the stockholders of the
Company.

 

(iii)                               Performance
Period; Timing for Establishing Performance Goals.  Achievement of performance goals in respect
of such Performance Awards shall be measured over a performance period of up to
ten years, as specified by the Committee. 
Performance goals shall be established not later than 90 days after the
beginning of any performance period applicable to such Performance Awards, or at
such other date as may be required or permitted for “performance-based
compensation” under section 162(m) of the Code.

 

(iv)                              Performance
Award Pool.  The Committee may
establish a Performance Award pool, which shall be an unfunded pool, for
purposes of measuring performance of the Company in connection with Performance
Awards.  The amount of such Performance
Award pool shall be based upon the achievement of a performance goal or goals
based on one or more of the criteria set forth in Section 8(b)(ii) hereof
during the given performance period, as specified by the Committee in
accordance with Section 8(b)(iii) hereof.  The Committee may specify the amount of the
Performance Award pool as a percentage of any of such criteria, a percentage
thereof in excess of a threshold amount, or as another amount which need not
bear a strictly mathematical relationship to such criteria.

 

(v)                                 Settlement
of Performance Awards; Other Terms. 
After the end of each performance period, the Committee shall determine
the amount, if any, of (A) the Performance Award pool, and the maximum
amount of potential Performance Award payable to each Participant in the
Performance Award pool, or (B) the amount of potential Performance Award
otherwise payable to each Participant. 
Settlement of such Performance Awards shall be in cash, Stock, other
Awards or other property, in the discretion of the Committee.  The Committee may, in its discretion, reduce
the amount of a settlement otherwise to be made in connection with such
Performance Awards, but may not exercise discretion to increase any such amount
payable to a Covered Employee in respect of a Performance Award subject to this

 

16

 

Section 8(b).  The Committee shall specify the circumstances
in which such Performance Awards shall be paid or forfeited in the event of
termination of employment by the Participant prior to the end of a performance
period or settlement of Performance Awards.

 

(c)                                  Annual Incentive Awards
Granted to Designated Covered Employees.  If the Committee determines that an Annual
Incentive Award to be granted to an Eligible Person who is designated by the
Committee as likely to be a Covered Employee should qualify as “performance-based
compensation” for purposes of section 162(m) of the Code, the grant,
exercise and/or settlement of such Annual Incentive Award shall be contingent
upon achievement of preestablished performance goals and other terms set forth
in this Section 8(c).

 

(i)                                     Annual
Incentive Award Pool.  The Committee
may establish an Annual Incentive Award pool, which shall be an unfunded pool,
for purposes of measuring performance of the Company in connection with Annual
Incentive Awards.  The amount of such
Annual Incentive Award pool shall be based upon the achievement of a
performance goal or goals based on one or more of the business criteria set
forth in Section 8(b)(ii) hereof during the given performance period,
as specified by the Committee in accordance with Section 8(b)(iii) hereof.  The Committee may specify the amount of the
Annual Incentive Award pool as a percentage of any of such business criteria, a
percentage thereof in excess of a threshold amount, or as another amount which
need not bear a strictly mathematical relationship to such business criteria.

 

(ii)                                  Potential
Annual Incentive Awards.  Not later
than the end of the 90th day of each fiscal year, or at such other date as may
be required or permitted in the case of Awards intended to be “performance-based
compensation” under section 162(m) of the Code, the Committee shall
determine the Eligible Persons who will potentially receive Annual Incentive
Awards, and the amounts potentially payable thereunder, for that fiscal year,
either out of an Annual Incentive Award pool established by such date under Section 8(c)(i) hereof
or as individual Annual Incentive Awards. 
In the case of individual Annual Incentive Awards intended to qualify
under section 162(m) of the Code, the amount potentially payable shall be
based upon the achievement of a performance goal or goals based on one or more
of the business criteria set forth in Section 8(b)(ii) hereof
in the given performance year, as specified by the Committee; in other cases,
such amount shall be based on such criteria as shall be established by the
Committee.  In all cases, the maximum
Annual Incentive Award of any Participant shall be subject to the limitation
set forth in Section 5 hereof.

 

(iii)                               Payout
of Annual Incentive Awards.  After
the end of each fiscal year, the Committee shall determine the amount, if any,
of (A) the Annual Incentive Award pool, and the maximum amount of
potential Annual Incentive Award payable to each Participant in the Annual
Incentive Award pool, or (B) the amount of potential Annual Incentive
Award otherwise payable to each Participant. 
The Committee may, in its discretion, determine that the amount payable
to any Participant as a final Annual Incentive Award shall be increased or
reduced from the amount of his or her potential Annual Incentive Award,
including a determination to make no final Award whatsoever, but may not
exercise discretion to increase any such amount in the case of an Annual
Incentive Award intended to qualify under section 162(m) of the Code.  The Committee shall specify the circumstances
in which an Annual Incentive Award shall be paid or

 

17

 

forfeited
in the event of termination of employment by the Participant prior to the end
of a fiscal year or settlement of such Annual Incentive Award.

 

(d)                                 Written Determinations.  All determinations by the Committee as to the
establishment of performance goals, the amount of any Performance Award pool or
potential individual Performance Awards and as to the achievement of
performance goals relating to Performance Awards under Section 8(b), and
the amount of any Annual Incentive Award pool or potential individual Annual
Incentive Awards and the amount of final Annual Incentive Awards under Section 8(c),
shall be made in writing in the case of any Award intended to qualify under section 162(m)
of the Code.  The Committee may not
delegate any responsibility relating to such Performance Awards or Annual
Incentive Awards.

 

(e)                                  Status of Section 8(b) and
Section 8(c) Awards under Section 162(m) of the Code.  It is the intent of the Company that
Performance Awards and Annual Incentive Awards under Sections 8(b) and 8(c) hereof
granted to persons who are designated by the Committee as likely to be Covered
Employees within the meaning of section 162(m) of the Code and regulations
thereunder (including Treasury Regulation §1.162-27 and successor
regulations thereto) shall, if so designated by the Committee, constitute “performance-based
compensation” within the meaning of section 162(m) of the Code and
regulations thereunder.  Accordingly, the
terms of Sections 8(b), (c), (d) and (e), including the definitions of
Covered Employee and other terms used therein, shall be interpreted in a manner
consistent with section 162(m) of the Code and regulations
thereunder.  The foregoing notwithstanding,
because the Committee cannot determine with certainty whether a given
Participant will be a Covered Employee with respect to a fiscal year that has
not yet been completed, the term Covered Employee as used herein shall mean
only a person designated by the Committee, at the time of grant of Performance
Awards or an Annual Incentive Award, who is likely to be a Covered Employee
with respect to that fiscal year.  If any
provision of this Plan as in effect on the date of adoption or any agreements
relating to Performance Awards or Annual Incentive Awards that are designated
as intended to comply with section 162(m) of the Code does not comply or
is inconsistent with the requirements of section 162(m) of the Code or
regulations thereunder, such provision shall be construed or deemed amended to
the extent necessary to conform to such requirements.

 

9.                                      Recapitalization or
Reorganization.

 

(a)                                  Existence of Plans and Awards.  The existence of this Plan and the Awards
granted hereunder shall not affect in any way the right or power of the Board
or the stockholders of the Company to make or authorize any adjustment,
recapitalization, reorganization or other change in the Company’s capital
structure or its business, any merger or consolidation of the Company, any issue
of debt or equity securities ahead of or affecting Stock or the rights thereof,
the dissolution or liquidation of the Company or any sale, lease, exchange or
other disposition of all or any part of its assets or business or any other
corporate act or proceeding.

 

(b)                                 Subdivision or Consolidation
of Shares.  The terms of an Award
and the number of shares of Stock authorized pursuant to Section 4 for
issuance under the Plan shall be subject to adjustment from time to time, in
accordance with the following provisions:

 

18

 

(i)                                     If
at any time, or from time to time, the Company shall subdivide as a whole (by
reclassification, by a Stock split, by the issuance of a distribution on Stock
payable in Stock, or otherwise) the number of shares of Stock then outstanding
into a greater number of shares of Stock, then (A) the maximum number of
shares of Stock available for the Plan as provided in Section 4 shall be
increased proportionately, and the kind of shares or other securities available
for the Plan shall be appropriately adjusted, (B) the number of shares of
Stock (or other kind of shares or securities) that may be acquired under any
Award shall be increased proportionately, and (C) the price (including the
exercise price) for each share of Stock (or other kind of shares or securities)
subject to then outstanding Awards shall be reduced proportionately, without
changing the aggregate purchase price or value as to which outstanding Awards
remain exercisable or subject to restrictions.

 

(ii)                                  If
at any time, or from time to time, the Company shall consolidate as a whole (by
reclassification, reverse Stock split, or otherwise) the number of shares of
Stock then outstanding into a lesser number of shares of Stock, (A) the
maximum number of shares of Stock available for the Plan as provided in Section 4
shall be decreased proportionately, and the kind of shares or other securities
available for the Plan shall be appropriately adjusted, (B) the number of
shares of Stock (or other kind of shares or securities) that may be acquired
under any Award shall be decreased proportionately, and (C) the price
(including the exercise price) for each share of Stock (or other kind of shares
or securities) subject to then outstanding Awards shall be increased
proportionately, without changing the aggregate purchase price or value as to
which outstanding Awards remain exercisable or subject to restrictions.

 

(iii)                               Whenever
the number of shares of Stock subject to outstanding Awards and the price for
each share of Stock subject to outstanding Awards are required to be adjusted
as provided in this Section 9(b), the Committee shall promptly prepare a
notice setting forth, in reasonable detail, the event requiring adjustment, the
amount of the adjustment, the method by which such adjustment was calculated,
and the change in price and the number of shares of Stock, other securities,
cash, or property purchasable subject to each Award after giving effect to the
adjustments.  The Committee shall promptly
give each Participant such a notice.

 

(iv)                              Adjustments
under Subsections 9(b)(i) and (ii) shall be
made by the Committee, and its determination as to what adjustments shall be
made and the extent thereof shall be final, binding, and conclusive.  No fractional interest shall be issued under
the Plan on account of any such adjustments.

 

(c)                                  Corporate Restructuring.  If the Company recapitalizes, reclassifies
its capital stock, or otherwise changes its capital structure (a “recapitalization”),
the number and class of shares of Stock covered by an Option theretofore
granted shall be adjusted so that such Option shall thereafter cover the number
and class of shares of stock and securities to which the holder would have been
entitled pursuant to the terms of the recapitalization if, immediately prior to
the recapitalization, the holder had been the holder of record of the number of
shares of Stock then covered by such Option and the share limitations provided
in Sections 4 and 5 shall be adjusted in a manner consistent with the
recapitalization.  Upon a Change in
Control the Committee, acting in its sole discretion without the consent or
approval of any holder, shall effect one or more of the following alternatives,
which may vary among individual holders and

 

19

 

which may vary among Options
held by any individual holder: (1) accelerate the time at which Options
then outstanding may be exercised so that such Options may be exercised in full
for a limited period of time on or before a specified date (before or after
such Change in Control) fixed by the Committee, after which specified date all
unexercised Options and all rights of holders thereunder shall terminate, (2) require
the mandatory surrender to the Company by selected holders of some or all of
the outstanding Options held by such holders (irrespective of whether such
Options are then exercisable under the provisions of this Plan) as of a date,
before or after such Change in Control, specified by the Committee, in which
event the Committee shall thereupon cancel such Options and pay to each holder
an amount of cash per share equal to the excess, if any, of the amount
calculated in Section 9(d) (the “Change in Control Price”) of the
shares subject to such Option over the exercise price(s) under such Options for
such shares, or (3) make such adjustments to Options then outstanding as
the Committee deems appropriate to reflect such Change in Control; provided,
however, that the Committee may determine in its sole discretion that no
adjustment is necessary to Options then outstanding; provided, further, that
the right to make such adjustments shall include, but not be limited to, the
modification of an Option such that the holder of the Option shall be entitled
to purchase or receive (in lieu of the total shares that the holder would
otherwise be entitled to purchase or receive under the Option (the “Total
Shares”)), the number of shares of stock, other securities, cash or property to
which the Total Shares would have been entitled to in connection with the
Change in Control, at an aggregate exercise price equal to the exercise price
that would have been payable if the Total Shares had been purchased upon the
exercise of the Option immediately before the consummation of the Change in
Control.

 

(d)                                 Change in Control Price.  The “Change in Control Price” shall equal the
amount determined in clause (i), (ii), (iii), (iv) or (v), whichever is
applicable, as follows:  (i) the per
share price offered to holders of the same class of Stock of the Company in any
such merger or consolidation, (ii) the per share value of the Stock
immediately before the Change in Control without regard to assets sold in the
Change in Control and assuming the Company has received the consideration paid
for the assets in the case of a sale of the assets, (iii) the amount
distributed per share of Stock in a dissolution transaction, (iv) the
price per share offered to holders of the same class of Stock of the Company in
any tender offer or exchange offer whereby a Change in Control takes place, or (v) if
such Change in Control occurs other than pursuant to a tender or exchange
offer, the fair market value per share of the shares into which such Options
being surrendered are exercisable, as determined by the Committee as of the
date determined by the Committee to be the date of cancellation and surrender
of such Options.  In the event that the
consideration offered to stockholders of the Company in any transaction described
in this Section 9(d) or Section 9(c) above consists of
anything other than cash, the Committee shall determine the fair cash
equivalent of the portion of the consideration offered which is other than
cash.

 

(e)                                  Non-Option Awards.  In the event of changes in the outstanding
Stock by reason of recapitalization, reorganizations, mergers, consolidations,
combinations, exchanges or other relevant changes in capitalization occurring
after the date of the grant of any Award and not otherwise provided for by this
Section 9, any outstanding Awards and any agreements evidencing such
Awards shall be subject to adjustment by the Committee at its discretion as to
the number and price of shares of Stock or other consideration subject to such
Awards.  In the event of any such change
in the outstanding Stock, the aggregate number of shares available

 

20

 

under
this Plan may be appropriately adjusted by the Committee, whose determination
shall be conclusive.

 

(f)                                    Additional Issuances.  Except as hereinbefore expressly provided,
the issuance by the Company of shares of stock of any class or securities
convertible into shares of stock of any class, for cash, property, labor or
services, upon direct sale, upon the exercise of rights or warrants to
subscribe therefor, or upon conversion of shares or obligations of the Company
convertible into such shares or other securities, and in any case whether or
not for fair value, shall not affect, and no adjustment by reason thereof shall
be made with respect to, the number of shares of Stock subject to Awards
theretofore granted or the purchase price per share, if applicable.

 

(g)                                 Restricted Stock Awards.  Plan provisions to the contrary
notwithstanding, with respect to any Restricted Stock Awards outstanding at the
time a Change in Control as described in Section 2(g) occurs, the
Committee may, in its discretion and as of a date determined by the Committee,
fully vest any or all Stock awarded to the holder pursuant to such Restricted
Stock Award and then outstanding and, upon such vesting, all restrictions
applicable to such Restricted Stock Award shall terminate as of such date.  Any action by the Committee pursuant to this Section 9(g) may
vary among individual holders and may vary among the Restricted Stock Awards
held by any individual holder.

 

10.                               General Provisions.

 

(a)                                  Transferability.

 

(i)                                     Permitted
Transferees.  The Committee may, in
its discretion, permit a Participant to transfer all or any portion of an
Option, Stock Appreciation Right, Phantom Stock Award or Restricted Stock Award
(if such Restricted Stock Award does not require the transfer of consideration
by the Participant or the holder other than usual and customary service) after
the Company’s initial registration of the Stock under section 12(b) or
12(g) of the Exchange Act, or authorize all or a portion of such Awards to
be granted to an Eligible Person to be on terms which permit transfer by such
Participant; provided that, in either case the transferee or transferees must
be any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including
adoptive relationships, in each case with respect to the Participant, any
person sharing the Participant’s household (other than a tenant or employee of
the Company), a trust in which these persons have more than fifty percent of
the beneficial interest, a foundation in which these persons (or the
Participant) control the management of assets, and any other entity in which
these persons (or the Participant) own more than fifty percent of the voting
interests (collectively, “Permitted Transferees”); provided further that, (X)
there may be no consideration for any such transfer and (Y) subsequent
transfers of Awards transferred as provided above shall be prohibited except
subsequent transfers back to the original holder of the Award and transfers to
other Permitted Transferees of the original holder.  Agreements evidencing Awards with respect to
which such transferability is authorized at the time of grant must be approved
by the Committee, and must expressly provide for transferability in a manner
consistent with this Subsection 10(a)(i).

 

21

 

(ii)                                  Qualified
Domestic Relations Orders.  An
Option, Stock Appreciation Right, Phantom Stock Award or Restricted Stock Award
(if such Restricted Stock Award does not require the transfer of consideration
by the Participant or the holder other than usual and customary service) after
the Company’s initial registration of the Stock under section 12(b) or
12(g) of the Exchange Act, may be transferred, to a Permitted Transferee,
pursuant to a domestic relations order entered or approved by a court of
competent jurisdiction upon delivery to the Company of written notice of such
transfer and a certified copy of such order.

 

(iii)                               Other
Transfers.  Except as expressly
permitted by Subsections 10(a)(i) and 10(a)(ii), Awards shall not be
transferable other than by will or the laws of descent and distribution except
that in the Committee’s discretion a Stock Appreciation Right, Phantom Stock
Award (if such Stock Appreciation Right or Phantom Stock Award is not
exercisable for Stock and not subject to the Participant’s or holder’s
discretion as to the timing or method of payment) or Restricted Stock Award (if
such Restricted Stock Award does not require the transfer of consideration by
the Participant or the holder other than usual and customary service) may be
transferable, however, not for consideration. 
Notwithstanding anything to the contrary in this Section 10, an
Incentive Stock Option shall not be transferable other than by will or the laws
of descent and distribution.

 

(iv)                              Effect
of Transfer.  Following the transfer
of any Award as contemplated by Subsections 10(a)(i), 10(a)(ii) and
10(a)(iii), (A) such Award shall continue to be subject to the same terms
and conditions as were applicable immediately prior to transfer, provided that
the term “Participant” shall be deemed to refer to the Permitted Transferee,
the recipient under a qualified domestic relations order, the estate or heirs
of a deceased Participant, or other transferee, as applicable, to the extent
appropriate to enable the Participant to exercise the transferred Award in
accordance with the terms of this Plan and applicable law and (B) the
provisions of the Award relating to exercisability hereof shall continue to be
applied with respect to the original Participant and, following the occurrence
of any such events described therein the Awards shall be exercisable by the
Permitted Transferee, the recipient under a qualified domestic relations order,
the estate or heirs of a deceased Participant, or other transferee, as
applicable, only to the extent and for the periods that would have been
applicable in the absence of the transfer.

 

(v)                                 Procedures
and Restrictions.  Any Participant
desiring to transfer an Award as permitted under Subsections 10(a)(i), 10(a)(ii) or 10(a)(iii) shall make application
therefor in the manner and time specified by the Committee and shall comply
with such other requirements as the Committee may require to assure compliance
with all applicable securities laws.  The
Committee shall not give permission for such a transfer if (A) it would
give rise to short-swing liability under section 16(b) of the
Exchange Act or (B) it may not be made in compliance with all applicable
federal, state and foreign securities laws.

 

(vi)                              Registration.  To the extent the issuance to any Permitted
Transferee of any shares of Stock issuable pursuant to Awards transferred as
permitted in this Section 10(a) is not registered pursuant to the
effective registration statement of the Company generally covering the shares
to be issued pursuant to this Plan to initial holders of Awards, the Company
shall not have any obligation to register the issuance of any such shares of
Stock to any such transferee.

 

22

 

(b)                                 Taxes. 
The Company and any Subsidiary is authorized to withhold from any Award
granted, or any payment relating to an Award under this Plan, including from a
distribution of Stock, amounts of withholding and other taxes due or
potentially payable in connection with any transaction involving an Award, and
to take such other action as the Committee may deem advisable to enable the
Company and Participants to satisfy obligations for the payment of withholding
taxes and other tax obligations relating to any Award.  This authority shall include authority to
withhold or receive Stock or other property and to make cash payments in
respect thereof in satisfaction of a Participant’s tax obligations, either on a
mandatory or elective basis in the discretion of the Committee.

 

(c)                                  Changes to this Plan and Awards.  The Board may amend, alter, suspend,
discontinue or terminate this Plan or the Committee’s authority to grant Awards
under this Plan without the consent of stockholders or Participants, except
that any amendment or alteration to this Plan, including any increase in any
share limitation, shall be subject to the approval of the Company’s
stockholders not later than the annual meeting next following such Board action
if such stockholder approval is required by any federal or state law or
regulation or the rules of any stock exchange or automated quotation
system on which the Stock may then be listed or quoted, and the Board may
otherwise, in its discretion, determine to submit other such changes to this
Plan to stockholders for approval; provided that, without the consent of an
affected Participant, no such Board action may materially and adversely affect
the rights of such Participant under any previously granted and outstanding
Award.  The Committee may waive any conditions
or rights under, or amend, alter, suspend, discontinue or terminate any Award
theretofore granted and any Award agreement relating thereto, except as
otherwise provided in this Plan; provided that, without the consent of an
affected Participant, no such Committee action may materially and adversely
affect the rights of such Participant under such Award.

 

(d)                                 Limitation on Rights
Conferred under Plan.  Neither
this Plan nor any action taken hereunder shall be construed as (i) giving
any Eligible Person or Participant the right to continue as an Eligible Person
or Participant or in the employ or service of the Company or a Subsidiary, (ii) interfering
in any way with the right of the Company or a Subsidiary to terminate any
Eligible Person’s or Participant’s employment or service at any time, (iii) giving
an Eligible Person or Participant any claim to be granted any Award under this
Plan or to be treated uniformly with other Participants and employees, or (iv) conferring
on a Participant any of the rights of a stockholder of the Company unless and
until the Participant is duly issued or transferred shares of Stock in
accordance with the terms of an Award.

 

(e)                                  Unfunded Status of Awards.  This Plan is intended to constitute an “unfunded”
plan for certain incentive awards.

 

(f)                                    Nonexclusivity of this Plan.  Neither the adoption of this Plan by the Board
nor its submission to the stockholders of the Company for approval shall be
construed as creating any limitations on the power of the Board or a committee
thereof to adopt such other incentive arrangements as it may deem desirable,
including incentive arrangements and awards which do not qualify under section 162(m)
of the Code.  Nothing contained in this
Plan shall be construed to prevent the Company or any Subsidiary from taking
any corporate action which is deemed by the Company or such Subsidiary to be
appropriate or in its 
best interest, whether or not such action would have an adverse
effect on this Plan or any Award made under this Plan.

 

23

 

No employee, beneficiary or
other person shall have any claim against the Company or any Subsidiary as a
result of any such action.

 

(g)                                 Payments in the Event of
Forfeitures; Fractional Shares. 
Unless otherwise determined by the Committee, in the event of a
forfeiture of an Award with respect to which a Participant paid cash or other
consideration to the Company in exchange for such Award, the Participant shall
be repaid the amount of such cash or other consideration.  No fractional shares of Stock shall be issued
or delivered pursuant to this Plan or any Award.  The Committee shall determine whether cash,
other Awards or other property shall be issued or paid in lieu of such
fractional shares or whether such fractional shares or any rights thereto shall
be forfeited or otherwise eliminated.

 

(h)                                 Severability.  If any provision of this Plan is held to
be illegal or invalid for any reason, the illegality or invalidity shall not
affect the remaining provisions hereof, but such provision shall be fully
severable and the Plan shall be construed and enforced as if the illegal or
invalid provision had never been included herein.  If any of the terms or provisions of this
Plan or any Award agreement conflict with the requirements of Rule 16b-3
(as those terms or provisions are applied to Eligible Persons who are subject
to section 16(b) of the Exchange Act) or section 422 of the Code
(with respect to Incentive Stock Options), then those conflicting terms or
provisions shall be deemed inoperative to the extent they so conflict with the
requirements of Rule 16b-3 (unless the Board or the Committee, as
appropriate, has expressly determined that the Plan or such Award should not
comply with Rule 16b-3) or section 422 of the Code.  With respect to Incentive Stock Options, if
this Plan does not contain any provision required to be included herein under section 422
of the Code, that provision shall be deemed to be incorporated herein with the
same force and effect as if that provision had been set out at length herein;
provided, further, that, to the extent any Option that is intended to qualify
as an Incentive Stock Option cannot so qualify, that Option (to that extent)
shall be deemed an Option not subject to section 422 of the Code for all
purposes of the Plan.

 

(i)                                     Governing Law.  All questions arising with respect to the
provisions of the Plan and Awards shall be determined by application of the
laws of the State of Delaware, without giving effect to any conflict of law
provisions thereof, except to the extent Delaware law is preempted by federal
law.  The obligation of the Company to
sell and deliver Stock hereunder is subject to applicable federal and state
laws and to the approval of any governmental authority required in connection
with the authorization, issuance, sale, or delivery of such Stock.

 

(j)                                     Conditions to Delivery of Stock.  Nothing herein or in any Award granted
hereunder or any Award agreement shall require the Company to issue any shares
with respect to any Award if that issuance would, in the opinion of counsel for
the Company, constitute a violation of the Securities Act or any similar or
superseding statute or statutes, any other applicable statute or regulation, or
the rules of any applicable securities exchange or securities association,
as then in effect.  At the time of any
exercise of an Option or Stock Appreciation Right, or at the time of any grant
of a Restricted Stock Award, the Company may, as a condition precedent to the
exercise of such Option or Stock Appreciation Right or vesting of any Restricted
Stock Award, require from the Participant (or in the event of his death, his
legal representatives, heirs, legatees, or distributees) such written
representations, if any, concerning the holder’s intentions with regard to the
retention or disposition of the shares of Stock being acquired

 

24

 

pursuant to the Award and such
written covenants and agreements, if any, as to the manner of disposal of such
shares as, in the opinion of counsel to the Company, may be necessary to ensure
that any disposition by that holder (or in the event of the holder’s death, his
legal representatives, heirs, legatees, or distributees) will not involve a
violation of the Securities Act or any similar or superseding statute or
statutes, any other applicable state or federal statute or regulation, or any rule of
any applicable securities exchange or securities association, as then in
effect.  No Option or Stock Appreciation
Right shall be exercisable and no restriction on any Restricted Stock Award
shall lapse with respect to a Participant unless and until the holder thereof
shall have paid cash or property to, or performed services for, the Company or
any of its Subsidiaries that the Committee believes is equal to or greater in value
than the par value of the Stock subject to such Award.

 

25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]